Attached files

file filename
EX-31.2 - EX-31.2 - IASIS Healthcare LLCd172963dex312.htm
EX-31.1 - EX-31.1 - IASIS Healthcare LLCd172963dex311.htm
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     .

COMMISSION FILE NUMBER: 333-117362

 

 

IASIS HEALTHCARE LLC

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   20-1150104

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

DOVER CENTRE

117 SEABOARD LANE, BUILDING E

FRANKLIN, TENNESSEE

  37067
(Address of principal executive offices)   (Zip Code)

(615) 844-2747

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES  ¨    NO  x

(Note: As a voluntary filer not subject to the filing requirements of Sections 13 or 15(d) of the Exchange Act, the registrant has filed all reports pursuant to Section 13 or 15(d) of the Exchange Act during the preceding 12 months as if it were subject to such filing requirements.)

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    YES  x    NO  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non-accelerated filer   x    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    YES  ¨    NO  x

As of May 16, 2016, 100% of the registrant’s common interests outstanding (all of which are privately owned and are not traded on any public market) were owned by IASIS Healthcare Corporation, its sole member.

 

 

 


Table of Contents

TABLE OF CONTENTS

 

PART I. FINANCIAL INFORMATION

     3   

Item 1. Financial Statements

     3   

Item  2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

     35   

Item 3. Quantitative and Qualitative Disclosures about Market Risk

     53   

Item 4. Controls and Procedures

     54   

PART II. OTHER INFORMATION

     54   

Item 1. Legal Proceedings

     54   

Item 1A. Risk Factors

     54   

Item 6. Exhibits

     54   

Signatures

     55   

 

2


Table of Contents

PART I.

FINANCIAL INFORMATION

 

Item 1. Financial Statements

IASIS HEALTHCARE LLC

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands)

 

     March 31,
2016
     September 30,
2015
 
     (unaudited)         
ASSETS      

Cash and cash equivalents

   $ 367,547       $ 378,513   

Accounts receivable, net

     342,413         317,729   

Inventories

     63,609         62,593   

Deferred income taxes

     —           2,645   

Prepaid expenses and other current assets

     167,268         200,555   
  

 

 

    

 

 

 

Total current assets

     940,837         962,035   

Property and equipment, net

     930,918         894,766   

Goodwill

     821,339         821,339   

Other intangible assets, net

     18,211         19,896   

Other assets, net

     60,706         55,596   
  

 

 

    

 

 

 

Total assets

   $ 2,772,011       $ 2,753,632   
  

 

 

    

 

 

 
LIABILITIES AND EQUITY      

Accounts payable

   $ 132,394       $ 131,152   

Salaries and benefits payable

     76,891         80,833   

Accrued interest payable

     27,715         26,896   

Medical claims payable

     132,504         104,296   

Other accrued expenses and current liabilities

     111,090         98,324   

Current portion of long-term debt, capital leases and other long-term obligations

     23,957         11,816   
  

 

 

    

 

 

 

Total current liabilities

     504,551         453,317   

Long-term debt, capital leases and other long-term obligations

     1,846,440         1,842,714   

Deferred income taxes

     105,632         118,477   

Other long-term liabilities

     93,373         95,553   

Non-controlling interests with redemption rights

     113,962         114,922   

Member’s equity

     94,487         117,847   

Non-controlling interests

     13,566         10,802   
  

 

 

    

 

 

 

Total equity

     108,053         128,649   
  

 

 

    

 

 

 

Total liabilities and equity

   $ 2,772,011       $ 2,753,632   
  

 

 

    

 

 

 

See accompanying notes.

 

3


Table of Contents

IASIS HEALTHCARE LLC

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(In Thousands)

 

     Quarter Ended
March 31,
    Six Months Ended
March 31,
 
     2016     2015     2016     2015  

Revenues

        

Acute care revenue before provision for bad debts

   $ 598,194      $ 551,590      $ 1,179,595      $ 1,105,506   

Less: Provision for bad debts

     (98,881     (80,726     (190,696     (170,078
  

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

     499,313        470,864        988,899        935,428   

Premium, service and other revenue

     321,974        225,963        635,236        430,937   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     821,287        696,827        1,624,135        1,366,365   

Costs and expenses

        

Salaries and benefits (includes stock-based compensation of $1,737, $1,841, $3,344 and $3,706, respectively)

     252,269        237,268        497,127        468,199   

Supplies

     84,113        80,140        168,964        160,191   

Medical claims

     268,030        176,059        534,737        352,031   

Rentals and leases

     21,968        19,088        43,300        37,797   

Other operating expenses

     148,137        113,746        277,887        226,967   

Medicare and Medicaid EHR incentives

     (48     (2,235     (490     (5,650

Interest expense, net

     34,033        31,854        66,643        64,217   

Depreciation and amortization

     27,057        21,555        53,250        44,186   

Management fees

     1,250        1,250        2,500        2,500   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

     836,809        678,725        1,643,918        1,350,438   

Earnings (loss) from continuing operations before gain (loss) on disposal of assets and income taxes

     (15,522     18,102        (19,783     15,927   

Gain (loss) on disposal of assets, net

     237        394        725        (454
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

     (15,285     18,496        (19,058     15,473   

Income tax expense (benefit)

     (4,885     9,747        (5,377     7,093   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) from continuing operations

     (10,400     8,749        (13,681     8,380   

Earnings (loss) from discontinued operations, net of income taxes

     167        (1,806     (3,886     (3,306
  

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss)

     (10,233     6,943        (17,567     5,074   

Net earnings attributable to non-controlling interests

     (2,602     (2,763     (5,403     (5,050
  

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) attributable to IASIS Healthcare LLC

   $ (12,835   $ 4,180      $ (22,970   $ 24   
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes.

 

4


Table of Contents

IASIS HEALTHCARE LLC

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

(In Thousands)

 

     Quarter Ended     Six Months Ended  
     March 31,     March 31,  
     2016     2015     2016     2015  

Net earnings (loss)

   $ (10,233   $ 6,943      $ (17,567   $ 5,074   

Other comprehensive income

        

Change in fair value of highly effective interest rate hedges

     487        339        976        745   
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income before income taxes

     487        339        976        745   

Change in income tax expense

     (178     (124     (356     (273
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income, net of income taxes

     309        215        620        472   
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

     (9,924     7,158        (16,947     5,546   

Net earnings attributable to non-controlling interests

     (2,602     (2,763     (5,403     (5,050
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to IASIS Healthcare LLC

   $ (12,526   $ 4,395      $ (22,350   $ 496   
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes.

 

5


Table of Contents

IASIS HEALTHCARE LLC

CONDENSED CONSOLIDATED STATEMENT OF EQUITY (UNAUDITED)

(In Thousands)

 

     Non-controlling                      
     Interests with            Non-         
     Redemption      Member’s     controlling         
     Rights      Equity     Interests      Total Equity  

Balance at September 30, 2015

   $ 114,922       $ 117,847      $ 10,802       $ 128,649   

Net earnings (loss)

     2,639         (22,970     2,764         (20,206

Distributions to non-controlling interests

     (5,563      —          —           —     

Repurchase of non-controlling interests

     (960      —          —           —     

Stock-based compensation

     —           3,344        —           3,344   

Other comprehensive income

     —           620        —           620   

Other

     (1,430      —          —           —     

Adjustment to redemption value of non-controlling interests with redemption rights

     4,354         (4,354     —           (4,354
  

 

 

    

 

 

   

 

 

    

 

 

 

Balance at March 31, 2016

   $ 113,962       $ 94,487      $ 13,566       $ 108,053   
  

 

 

    

 

 

   

 

 

    

 

 

 

See accompanying notes.

 

6


Table of Contents

IASIS HEALTHCARE LLC

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(In Thousands)

 

     Six Months Ended  
     March 31,  
     2016     2015  

Cash flows from operating activities

    

Net earnings (loss)

   $ (17,567   $ 5,074   

Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:

    

Depreciation and amortization

     53,250        44,186   

Amortization of loan costs

     4,012        3,942   

Amortization of deferred gain on sale-leaseback transaction

     (1,248     (1,248

Change in physician minimum revenue guarantees

     2,050        1,871   

Stock-based compensation

     3,344        3,706   

Deferred income taxes

     (8,512     7,967   

Loss (gain) on disposal of assets, net

     (725     454   

Loss from discontinued operations, net

     3,886        3,306   

Changes in operating assets and liabilities, net of the effect of acquisitions and dispositions:

    

Accounts receivable, net

     (24,684     (27,323

Inventories, prepaid expenses and other current assets

     30,091        (42,615

Accounts payable, other accrued expenses and other accrued liabilities

     34,155        18,623   
  

 

 

   

 

 

 

Net cash provided by operating activities — continuing operations

     78,052        17,943   

Net cash provided by (used in) operating activities — discontinued operations

     637        (755
  

 

 

   

 

 

 

Net cash provided by operating activities

     78,689        17,188   
  

 

 

   

 

 

 

Cash flows from investing activities

    

Purchases of property and equipment

     (62,050     (56,281

Cash paid for acquisitions, net

     (2,311     (3,900

Cash received (paid) related to divestiture

     (5,869     41,364   

Proceeds from sale of assets

     166        337   

Change in other assets, net

     399        (797
  

 

 

   

 

 

 

Net cash used in investing activities — continuing operations

     (69,665     (19,277

Net cash used in investing activities — discontinued operations

     —          (341
  

 

 

   

 

 

 

Net cash used in investing activities

     (69,665     (19,618
  

 

 

   

 

 

 

Cash flows from financing activities

    

Payment of long-term debt, capital leases and other long-term obligations

     (8,288     (6,708

Payment of debt financing costs

     (5,179     —     

Distributions to non-controlling interests

     (5,563     (4,438

Cash paid for the repurchase of non-controlling interests

     (960     (1,018
  

 

 

   

 

 

 

Net cash used in financing activities — continuing operations

     (19,990     (12,164

Net cash used in financing activities — discontinued operations

     —          (6
  

 

 

   

 

 

 

Net cash used in financing activities

     (19,990     (12,170
  

 

 

   

 

 

 

Change in cash and cash equivalents

     (10,966     (14,600

Cash and cash equivalents at beginning of period

     378,513        341,180   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 367,547      $ 326,580   
  

 

 

   

 

 

 

Supplemental disclosure of cash flow information:

    

Cash paid for interest

   $ 60,258      $ 61,991   
  

 

 

   

 

 

 

Cash paid for (received from) income taxes, net

   $ (11,411   $ 12,366   
  

 

 

   

 

 

 

Supplemental disclosure of non-cash information:

    

Financing obligation related to integrated clinical and revenue cycle system conversion

   $ 23,409      $ —     
  

 

 

   

 

 

 

See accompanying notes.

 

7


Table of Contents

IASIS HEALTHCARE LLC

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. ORGANIZATION AND BASIS OF PRESENTATION

Organization

The unaudited condensed consolidated financial statements as of and for the quarters and six months ended March 31, 2016 and 2015, reflect the financial position, results of operations and cash flows of IASIS Healthcare LLC (“IASIS” or the “Company”). The Company’s sole member and parent company is IASIS Healthcare Corporation (“Holdings” or “IAS”).

IASIS provides high quality affordable healthcare services primarily in higher growth markets. At March 31, 2016, we owned or leased 17 acute care hospital facilities and one behavioral health hospital facility with a total of 3,661 licensed beds, several outpatient service facilities and 147 physician clinics.

IASIS’ continuing operations are in various regions including:

 

    Salt Lake City, Utah;

 

    Phoenix, Arizona;

 

    six cities in Texas, including Houston and San Antonio; and

 

    West Monroe, Louisiana.

The Company also owns and operates a managed care organization and insurer that manages healthcare services for more than 656,200 members through Health Choice Arizona, Inc. and related entities (“Health Choice” or the “Plan”), which includes multiple health plans, accountable care networks and managed care solutions. The Plan is headquartered in Phoenix, Arizona, with offices in Tampa, Florida and Salt Lake City, Utah.

The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting and in accordance with Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet of the Company at September 30, 2015, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and notes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2015, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 22, 2015.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all material adjustments (consisting of normal recurring items) necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year or any other future periods.

Principles of Consolidation

The unaudited condensed consolidated financial statements include the consolidated financial position and consolidated results of operations of the Company and its affiliates, which are controlled by the Company through the Company’s direct or indirect ownership of a majority interest and rights granted to the Company through certain variable interests. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying unaudited condensed consolidated financial statements and notes. Actual results could differ from those estimates.

General and Administrative

The majority of the Company’s expenses are “cost of revenue” items. Costs that could be classified as “general and administrative” by the Company include the IASIS corporate office costs (excluding stock-based compensation costs), which were $13.5 million and $12.9 million for the quarters ended March 31, 2016 and 2015, respectively, and $24.5 million and $27.5 million for the six months ended March 31, 2016 and 2015, respectively.

 

8


Table of Contents

Cash and Cash Equivalents

The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. The Company maintains its cash and cash equivalent balances primarily with high credit quality financial institutions. The Company manages its credit exposure by placing its investments in U.S. Treasury securities or other high quality securities, and by periodically evaluating the relative credit standing of the financial institution.

As discussed in Note 3, cash generated from certain asset dispositions may be subject to prepayment requirements under our senior credit agreement and indenture.

As of March 31, 2016, the Company has restricted the use of $3.9 million of cash primarily for the purpose of meeting certain risk-based capital requirements in the Company’s managed care operations.

Stock-Based Compensation

Although IASIS has no stock option plan, or outstanding stock options or other equity awards, the Company, through its parent, IAS, grants stock options for a fixed number of common shares and restricted stock units (“RSUs”) to its employees. The Company accounts for these stock-based incentive awards under the measurement and recognition provisions of Accounting Standards Codification (“ASC”) 718, Compensation—Stock Compensation (“ASC 718”). Accordingly, the Company applies the fair value recognition provisions requiring all share-based payments to employees, including grants of employee stock options and RSUs, to be measured based on the grant-date fair value of the awards, with the resulting expense recognized in the income statement. In accordance with the provisions of ASC 718, the Company uses the Black-Scholes-Merton valuation model in determining the fair value of its share-based payments. Compensation cost for time-vested options and RSUs will generally be amortized on a straight-line basis over the requisite service periods of the awards, generally equal to the awards’ vesting periods, while compensation cost for options with market-based conditions are recognized on a graded schedule generally over the awards’ vesting periods.

Fair Value of Financial Instruments

The Company applies the provisions of ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), which provides a single definition of fair value, establishes a framework for measuring fair value, and expands disclosures concerning fair value measurements. The Company applies these provisions to the valuation and disclosure of certain financial instruments. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: (i) Level 1, which is defined as quoted prices in active markets that can be accessed at the measurement date; (ii) Level 2, which is defined as inputs other than quoted prices in active markets that are observable, either directly or indirectly; and (iii) Level 3, which is defined as unobservable inputs resulting from the existence of little or no market data, therefore potentially requiring an entity to develop its own assumptions.

Cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other current assets, accounts payable, salaries and benefits payable, accrued interest, medical claims payable, and other accrued expenses and current liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate fair value because of the short-term nature of these instruments. The fair value of the Company’s capital leases and other long-term financing obligations also approximate their carrying value as they bear interest at current market rates.

The carrying value and fair value of the Company’s senior secured term loan facility and its 8.375% senior notes due 2019 (the “Senior Notes”) as of March 31, 2016 and September 30, 2015, were as follows (in thousands):

 

     Carrying Amount      Fair Value  
     March 31,
2016
     September 30,
2015
     March 31,
2016
     September 30,
2015
 

Senior secured term loan facility

   $ 972,808       $ 977,477       $ 969,461       $ 980,592   

Senior Notes

     847,531         847,147         837,152         875,397   

The estimated fair value of the Company’s senior secured term loan facility and its Senior Notes were based upon quoted market prices at that date and are categorized as Level 2 within the fair value hierarchy.

 

9


Table of Contents

Discontinued Operations

In accordance with the provisions of ASC 360, Property, Plant and Equipment (“ASC 360”), the Company has presented the operating results, financial position and cash flows of its previously disposed facilities as discontinued operations, net of income taxes, in the accompanying unaudited condensed consolidated financial statements. Additionally, the Company includes in discontinued operations facilities that are part of an approved and committed plan to sell or dispose.

The following table provides the components of discontinued operations (in thousands):

 

     Quarter Ended
March 31,
     Six Months Ended
March 31,
 
     2016      2015      2016      2015  

Acute care revenue less provision for bad debts

   $ (70    $ 6,691       $ (410    $ 29,863   

Earnings (loss) before income taxes

     270         (4,717      (5,982      (6,873

Income tax expense (benefit) from discontinued operations

     103         (2,911      (2,096      (3,567
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from discontinued operations, net of income taxes

   $ 167       $ (1,806    $ (3,886    $ (3,306
  

 

 

    

 

 

    

 

 

    

 

 

 

Effective January 23, 2015, the Company completed the sale of its Nevada operations. The aggregate proceeds from the sale were $36.1 million (net of final working capital settlement), which resulted in a loss on the sale of assets totaling $14.4 million. Of this loss, $0.4 million and $7.5 million was recognized in the years ended September 30, 2015 and 2014, respectively. During the six months ended March 31, 2016, the Company recognized an additional $5.9 million loss related to the settlement of net working capital. The loss is included in discontinued operations in the accompanying unaudited condensed consolidated statement of operations.

Recent Accounting Pronouncements

Newly Adopted

In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, “Presentation of Financial Statements and Property, Plant, and Equipment—Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity”. Among other provisions and in addition to expanded disclosures, ASU No. 2014-08 changes the definition of what components of an entity qualify for discontinued operations treatment and reporting from a reportable segment, operating segment, reporting unit, subsidiary or asset group to only those components of an entity that represent a strategic shift that has, or will have, a major effect on an entity’s operations and financial results. Additionally, ASU No. 2014-08 requires disclosure about a disposal of an individually significant component of an entity that does not qualify for discontinued operations presentation in the financial statements, including the pretax profit or loss attributable to the component of an entity for the period in which it is disposed of or is classified as held for sale. The disclosure of this information is required for all of the same periods that are presented in the entity’s results of operations for the period. The provisions of ASU No. 2014-08 are effective prospectively for all disposals or classifications as held for sale of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The Company’s adoption of this authoritative guidance effective October 1, 2015, did not impact its unaudited condensed consolidated financial statements.

In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes”. Under ASU No. 2015-17, organizations that present a classified balance sheet are required to classify all deferred taxes as noncurrent assets or noncurrent liabilities. The provisions of ASU No. 2015-17 are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for all entities as of the beginning of an interim or annual reporting period. The Company has adopted ASU No. 2015-17, and accordingly, all deferred taxes are classified as noncurrent liabilities in the Company’s accompanying unaudited condensed consolidated balance sheet at March 31, 2016.

Recently Issued

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers”, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. In addition, ASU No. 2014-09 will require new and enhanced disclosures. Companies can adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. ASU No. 2014-09 was originally scheduled to become effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, and early adoption was not permitted. In July 2015, the FASB decided that a deferral was necessary to provide companies adequate time to effectively implement the new standard. The FASB deferred the effective date by one year, but will permit entities to adopt one year earlier if they so choose. The Company is currently evaluating the effect of the new revenue recognition guidance.

 

10


Table of Contents

In February 2015, the FASB issued ASU No. 2015-2, “Consolidation”. ASU No. 2015-2 includes amendments that are intended to improve targeted areas of consolidation for legal entities including reducing the number of consolidation models from four to two and simplifying the FASB ASC. The provisions of ASU No. 2015-2 are effective for annual periods beginning after December 15, 2015. The amendments may be applied retrospectively in previously issued financial statements for one or more years with a cumulative effect adjustment to retained earnings as of the beginning of the first year restated. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU No. 2015-2 will have on its financial position, results of operation, cash flows and financial disclosures.

In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs”, which requires that debt issuance costs be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The guidance in the new standard is limited to the presentation of debt issuance costs. The recognition and measurement guidance for debt issuance costs are not affected by ASU No. 2015-03. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU No. 2015-03 will have on its financial position, cash flows and financial disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases”, which requires lessees to recognize lease assets and lease liabilities on the balance sheet, including leases previously classified as operating. In addition, ASU 2016-02 implements changes to the lease classification criteria for lessors and eliminates portions of the previous real estate leasing guidance. ASU 2016-02 will become effective for fiscal years beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the effect of the new lease accounting guidance. We believe the primary effect of adopting the new standard will be to record assets and obligations for current operating leases.

In March 2016, the FASB issued ASU 2016-09 “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”, which affects all entities that issue share-based payment awards to their employees. ASU 2016-09 simplifies the accounting for share-based payment transactions, including the income tax consequences and classification on the balance sheet and statement of cash flows. Portions of the guidance will only impact non-public entities. ASU 2016-09 will become effective for fiscal years beginning after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the effect of the new share-based payment accounting guidance.

2. REVENUE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

Acute Care Revenue and Accounts Receivable

The Company’s healthcare facilities have entered into agreements with third-party payors, including government programs (Medicare, Medicaid and TRICARE), managed care health plans, including Medicare and Medicaid managed care health plans, commercial insurance companies and employers under which the facilities are paid based upon established charges, the cost of providing services, predetermined rates per diagnosis, fixed per diem rates or discounts from established charges. Additionally, the Company offers discounts through its uninsured discount program to all uninsured patients receiving healthcare services who do not qualify for assistance under state Medicaid, other federal or state assistance plans, or charity care.

In the ordinary course of business, the Company provides care without charge to patients who are financially unable to pay for the healthcare services they receive. Because the Company does not pursue collection of amounts determined to qualify as charity care, they are not reported in acute care revenue. Accordingly, the Company records revenue deductions for patient accounts that meet its guidelines for charity care. The Company provides charity care to patients with income levels below 200% of the federal poverty level (“FPL”). Additionally, at all of the Company’s hospitals, a sliding scale of reduced rates is offered to uninsured patients who are not covered through federal, state or private insurance, with incomes between 200% and 400% of the FPL.

Acute care revenue is reported at the estimated net realizable amounts from third-party payors and others for services rendered, including estimated retroactive adjustments under reimbursement agreements with third-party payors. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and are adjusted, if necessary, in future periods when final settlements are determined. The Company also records a provision for bad debts related to uninsured accounts, as well as co-insurance

 

11


Table of Contents

and deductible balances due from insured patients, to reflect its self-pay accounts receivable at the estimated amounts expected to be collected. The sources of the Company’s hospital net patient revenue by payor before its provision for bad debts are summarized as follows:

 

     Quarter Ended
March 31,
    Six Months Ended
March 31,
 
     2016     2015     2016     2015  

Medicare

     18.2     20.5     18.9     19.8

Managed Medicare

     10.3        10.1        10.4        10.1   

Medicaid and managed Medicaid

     11.9        12.8        12.4        12.7   

Managed care and other

     44.3        41.3        43.4        41.9   

Self-pay

     15.3        15.3        14.9        15.5   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total

     100.0     100.0     100.0     100.0
  

 

 

   

 

 

   

 

 

   

 

 

 

Allowance For Doubtful Accounts

The provision for bad debts and the associated allowance for doubtful accounts relate primarily to amounts due directly from patients. The Company does not pursue collection of amounts related to patients who qualify for charity care under the Company’s guidelines; therefore, charity care accounts are deducted from gross revenue and are not included in the provision for bad debts.

The Company’s estimation of its allowance for doubtful accounts is based primarily upon the type and age of the patient accounts receivable and the effectiveness of related collection efforts. The Company’s policy is to reserve a portion of all self-pay receivables, including amounts due from the uninsured and amounts related to co-payments and deductibles, as these charges are recorded. The Company monitors accounts receivable balances and the effectiveness of reserve policies on a regular basis and reviews various analytics to support the basis for its estimates. These efforts primarily consist of reviewing the following:

 

    Cash collections as a percentage of net patient revenue less bad debts;

 

    Changes in the aging and payor mix of accounts receivable, including increased focus on accounts due from the uninsured and accounts that represent co-payments and deductibles due from patients;

 

    Revenue and volume trends by payor, particularly the self-pay components;

 

    Trending of days revenue in accounts receivable;

 

    Various allowance coverage statistics; and

 

    Historical write-off and collection experience using a hindsight or look-back approach.

At March 31, 2016 and September 30, 2015, the Company’s net self-pay receivables, including amounts due from uninsured patients and co-payment and deductible amounts due from insured patients, were $275.0 million and $276.7 million, respectively. At March 31, 2016 and September 30, 2015, the Company’s allowance for doubtful accounts was $211.4 million and $210.1 million, respectively.

Premium, Service and Other Revenue

Health Choice is the Company’s managed care organization and insurer that serves health plan enrollees in Arizona and Utah. The Plan derives most of its revenue through a contract in Arizona with the Arizona Health Care Cost Containment System (“AHCCCS”) to provide specified health services to qualified Medicaid enrollees through contracted providers. AHCCCS is the state agency that administers Arizona’s Medicaid program.

Effective October 1, 2013, Health Choice entered into a contract with AHCCCS with an initial term of three years, and two one-year renewal options at the discretion of AHCCCS. The contract is terminable without cause on 90 days’ written notice or for cause upon written notice if the Company fails to comply with any term or condition of the contract or fails to take corrective action as required to comply with the terms of the contract. Additionally, AHCCCS can terminate the contract in the event of the unavailability of state or federal funding.

Health Choice also provides coverage as a Medicare Advantage Prescription Drug (“MAPD”) Special Needs Plan (“SNP”) provider pursuant to a contract with the Centers for Medicare and Medicaid Services (“CMS”). The SNP allows Health Choice to offer Medicare and Part D drug benefit coverage for new and existing dual-eligible members (i.e. those that are eligible for Medicare and Medicaid). The contract with CMS includes successive one-year renewal options at the discretion of CMS and is terminable without cause on 90 days’ written notice or for cause upon written notice if the Company fails to comply with any term or condition of the contract or fails to take corrective action as required to comply with the terms of the contract.

 

12


Table of Contents

In Arizona and surrounding states, the Plan subcontracts with hospitals, physicians and other medical providers to provide services to its Medicaid and Medicare enrollees in Apache, Coconino, Gila, Maricopa, Mohave, Navajo, Pima and Pinal counties, regardless of the actual costs incurred to provide these services.

Effective October 1, 2015, Health Choice’s joint venture, Health Choice Integrated Care LLC (“HCIC”) entered into a contract with the Arizona Department of Health Services (“ADHS”) to operate an integrated acute and behavioral health plan in Northern Arizona. The contract has an initial term of three years and includes two additional two-year renewal options that can be exercised at the discretion of ADHS. The contract is terminable by ADHS following HCIC’s failure to carry out a material contract term, condition or obligation. As of March 31, 2016, HCIC provided standalone behavioral health benefits for 226,200 plan members.

The Plan’s contracts require the arrangement of healthcare services for enrolled patients in exchange for fixed monthly premiums, based upon negotiated per capita member rates. Capitation payments received by Health Choice are recognized as revenue in the month that members are entitled to healthcare services. Premium revenue includes adjustments to revenue related to the program settlement process for the Arizona managed Medicaid plan under the related state contract. This program settlement process reconciles estimated amounts due to or from the state based on the actual premium revenue and medical costs and contractually mandated limits on profits and losses. Although estimates of future program settlement amounts are recorded in current periods, the program settlement process typically occurs 18 months post-plan year, when actual (rather than projected) claims and member eligibility data become available and a net settlement amount is either due to or from the state. Adjustments to the estimates of future program settlement amounts are recorded as a component of premium revenue.

The sources of Health Choice’s premium, service and other revenue by major product line are summarized as follows:

 

     Quarter Ended
March 31,
    Six Months Ended
March 31,
 
     2016     2015     2016     2015  

Medicaid and Exchange plans

     87.4     81.5     86.9     81.8

MAPD SNP

     9.7        13.4        9.8        13.7   

Service and other

     2.9        5.1        3.3        4.5   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total

     100.0     100.0     100.0     100.0
  

 

 

   

 

 

   

 

 

   

 

 

 

3. LONG-TERM DEBT, CAPITAL LEASES AND OTHER LONG-TERM OBLIGATIONS

Long-term debt, capital leases and other long-term obligations consist of the following (in thousands):

 

     March 31,
2016
     September 30,
2015
 

Senior secured term loan facility

   $ 972,808       $ 977,477   

Senior Notes

     847,531         847,147   

Capital leases and other long-term obligations

     50,058         29,906   
  

 

 

    

 

 

 
     1,870,397         1,854,530   

Less current maturities

     23,957         11,816   
  

 

 

    

 

 

 
   $ 1,846,440       $ 1,842,714   
  

 

 

    

 

 

 

As of March 31, 2016 and September 30, 2015, the senior secured term loan facility balance reflects an original issue discount (“OID”) of $1.6 million and $1.9 million, respectively, which is net of accumulated amortization of $3.5 million and $3.2 million, respectively. The Senior Notes balance reflects an OID of $2.4 million and $2.7 million, respectively, which is net of accumulated amortization of $3.7 million and $3.4 million, respectively.

As of March 31, 2016 and September 30, 2015, capital leases and other long-term obligations includes financing obligations totaling $21.1 million and $21.7 million, respectively, resulting from the Company’s sale-leaseback transactions. Additionally, as of March 31, 2016, capital leases and other long-term obligations includes a financing obligation totaling $21.0 million related to the Company’s current conversion to a new integrated clinical and revenue cycle system.

 

13


Table of Contents

Senior Secured Credit Facilities

Amended Term Loan Facility

The Company is party to a senior credit agreement (the “Amended and Restated Credit Agreement”) with Wilmington Trust, National Association, as administrative agent, which provides for a $1.025 billion senior secured term loan facility maturing in May 2018 (the “Term Loan Facility”). Principal under the Term Loan Facility is due in equal quarterly installments in an aggregate annual amount equal to 1% of the principal amount of $1.007 billion outstanding as of the effective date, February 20, 2013, of a repricing amendment, with the remaining balance due upon maturity of the Term Loan Facility.

Borrowings under the Term Loan Facility bear interest at a rate per annum equal to, at the Company’s option, either (1) a base rate determined by reference to the highest of (a) the federal funds rate plus 0.50%, (b) the prime rate (determined by reference to The Wall Street Journal) and (c) a one-month LIBOR rate, subject to a floor of 1.25%, plus 1.00%, in each case, plus a margin of 2.25% per annum or (2) the LIBOR rate for the interest period relevant to such borrowing, subject to a floor of 1.25%, plus a margin of 3.25% per annum.

The Term Loan Facility is unconditionally guaranteed by IAS and certain subsidiaries of the Company (collectively, the “Subsidiary Guarantors”; IAS and the Subsidiary Guarantors, the “Guarantors”) and is required to be guaranteed by all future material wholly-owned subsidiaries of the Company, subject to certain exceptions. All obligations under the Amended and Restated Credit Agreement are secured, subject to certain exceptions, by substantially all of the Company’s assets and the assets of the Guarantors, including (1) a pledge of 100% of the equity interests of the Company and the equity interests held by the Company and the Subsidiary Guarantors, subject to certain exceptions, (2) mortgage liens on all of the Company’s material real property and that of the Guarantors and (3) all proceeds of the foregoing.

The Amended and Restated Credit Agreement requires the Company to mandatorily prepay borrowings under the Term Loan Facility with net cash proceeds of certain asset dispositions, following certain casualty events, following certain borrowings or debt issuances and from a percentage of annual excess cash flow.

The Amended and Restated Credit Agreement contains certain restrictive covenants, including, among other things: (1) limitations on the incurrence of debt and liens; (2) limitations on investments other than, among other exceptions, certain acquisitions that meet certain conditions; (3) limitations on the sale of assets outside of the ordinary course of business; (4) limitations on dividends and distributions; and (5) limitations on transactions with affiliates, in each case, subject to certain exceptions. The Amended and Restated Credit Agreement also contains certain customary events of default, including, without limitation, a failure to make payments under the Term Loan Facility, cross-defaults, certain bankruptcy events and certain change of control events.

Revolving Credit Facility

The Company is party to a revolving credit agreement (the “Revolving Credit Agreement”) with JPMorgan Chase Bank, N.A. (“JPMorgan”), as administrative agent, which provides for a $207.4 million senior secured revolving credit facility, of which up to $125.0 million may be utilized for the issuance of letters of credit (the “Revolving Credit Facility”). The Revolving Credit Facility matures in February 2021 (the “Stated Revolver Maturity Date”), provided that, if prior to the Stated Revolver Maturity Date, (x) any loans are outstanding under the Term Loan Facility on the date that is 91 days prior to the maturity date under the Term Loan Facility (such date, the “Springing Term Maturity Date”) or (y) any notes are outstanding under the Company’s indenture, dated as of May 3, 2011, by and among IASIS, IAS and The Bank of New York Mellon Trust Company, N.A., as Trustee, relating to the Company’s 8.375% Senior Notes due 2019 (the “Indenture”), on the date that is 91 days prior to the maturity date under the Indenture (such date, the “Springing Notes Maturity Date”), then the maturity date will automatically become the earlier of the Springing Term Maturity Date or the Springing Notes Maturity Date.

The Revolving Credit Agreement provides the Company with the right to request additional commitments under the Revolving Credit Facility without the consent of the lenders thereunder, subject to a cap on aggregate commitments of $300.0 million, a pro forma senior secured net leverage ratio (as defined in the Revolving Credit Agreement) of less than or equal to 3.75 to 1.00 and customary conditions precedent.

The Revolving Credit Facility does not require installment payments prior to maturity.

Borrowings under the Revolving Credit Facility bear interest at a rate per annum equal to, at the Company’s option, either (1) a base rate determined by reference to the highest of (a) the prime rate of JPMorgan, (2) the federal funds rate plus 0.50% and (3) a LIBOR rate subject to certain adjustments plus 1.00%, in each case, plus a margin of 2.50% per annum or (2) the LIBOR rate for the interest period relevant to such borrowing, plus a margin of 3.50% per annum. In addition to paying interest on outstanding principal under the Revolving Credit Facility, the Company is required to pay a commitment fee on the unutilized commitments under the Revolving Credit Facility, as well as pay customary letter of credit fees and agency fees.

The Revolving Credit Facility is unconditionally guaranteed by the Guarantors and is required to be guaranteed by all future material wholly-owned subsidiaries of the Company, subject to certain exceptions. All obligations under the Revolving Credit Agreement are secured, subject to certain exceptions, by substantially all of the Company’s assets and the assets of the Guarantors, including (1) a pledge of 100% of the equity interests of the Company and the equity interests held by the Company and the Subsidiary Guarantors, subject to certain exceptions, (2) mortgage liens on all of the Company’s material real property and that of the Guarantors and (3) all proceeds of the foregoing.

 

14


Table of Contents

The Revolving Credit Agreement contains restrictive covenants and events of default substantially similar to the restrictive covenants and events of default in the Amended and Restated Credit Agreement; provided, that under the Revolving Credit Agreement, the Company is required to maintain, on a quarterly basis, a maximum senior secured gross leverage ratio (as defined in the Revolving Credit Agreement). In addition, certain of the baskets available to the Company under the negative covenants in the Amended and Restated Credit Agreement are suspended under the Revolving Credit Agreement until such time, if any, as the Company has consummated a qualifying underwritten public offering and achieved a specified total gross leverage ratio (as defined in the Revolving Credit Agreement).

8.375% Senior Notes due 2019

The Company, together with its wholly owned subsidiary IASIS Capital Corporation (together, the “Issuers”), issued $850.0 million aggregate principal amount of Senior Notes, which mature on May 15, 2019, pursuant to the Indenture. The Indenture provides that the Senior Notes are general unsecured, senior obligations of the Issuers, and initially will be unconditionally guaranteed on a senior unsecured basis by certain of the Company’s subsidiaries.

At March 31, 2016, the outstanding principal balance of the Senior Notes was $849.9 million. The Senior Notes bear interest at a rate of 8.375% per annum, payable semi-annually, in cash in arrears, on May 15 and November 15 of each year.

The Issuers may redeem the Senior Notes, in whole or in part, at any time, at a price equal to 102.094% of the aggregate principal amount of the Senior Notes plus accrued and unpaid interest and special interest, if any, to but excluding the redemption date. Each subsequent year the redemption price declines 2.094 percentage points until 2017, at which point and thereafter the redemption price is equal to 100% of the aggregate principal amount of the Senior Notes plus accrued and unpaid interest and special interest, if any, to but excluding the redemption date.

The Indenture contains covenants that limit the Company’s (and its restricted subsidiaries’) ability to, among other things: (1) incur additional indebtedness or liens or issue disqualified stock or preferred stock; (2) pay dividends or make other distributions on, redeem or repurchase the Company’s capital stock; (3) sell certain assets; (4) make certain loans and investments; (5) enter into certain transactions with affiliates; (6) impose restrictions on the ability of a subsidiary to pay dividends or make payments or distributions to the Company and its restricted subsidiaries; and (7) consolidate, merge or sell all or substantially all of the Company’s assets. These covenants are subject to a number of important limitations and exceptions.

The Indenture also provides for events of default, which, if any of them occurs, may permit or, in certain circumstances, require the principal, premium, if any, interest and any other monetary obligations on all the then outstanding Senior Notes to be due and payable immediately. If the Company experiences certain kinds of changes of control, it must offer to purchase the Senior Notes at 101% of their principal amount, plus accrued and unpaid interest and special interest, if any, to but excluding the repurchase date. Under certain circumstances, the Company will have the ability to make certain payments to facilitate a change of control transaction and to provide for the assumption of the Senior Notes by a new parent company resulting from such change of control transaction. If such change of control transaction is facilitated, the Issuers will be released from all obligations under the Indenture and the Issuers and the trustee will execute a supplemental indenture effectuating such assumption and release.

4. GOODWILL

The following table presents the changes, if any, in the carrying amount of goodwill (in thousands):

 

     Acute
Care
     Health
Choice
     Total  

Balance at September 30, 2015

   $ 815,582       $ 5,757       $ 821,339   

Adjustments

     —           —          —     
  

 

 

    

 

 

    

 

 

 

Balance at March 31, 2016

   $ 815,582       $ 5,757       $ 821,339   
  

 

 

    

 

 

    

 

 

 

5. ACCUMULATED OTHER COMPREHENSIVE LOSS

The components of accumulated other comprehensive loss, net of income taxes, are as follows (in thousands):

 

     March 31,
2016
     September 30,
2015
 

Fair value of interest rate hedges

   $ (994    $ (1,970

Income tax benefit

     492         848   
  

 

 

    

 

 

 

Accumulated other comprehensive loss

   $ (502    $ (1,122
  

 

 

    

 

 

 

 

15


Table of Contents

6. INCOME TAXES

For the quarter ended March 31, 2016, the Company recorded an income tax benefit of $4.9 million, resulting in an effective tax rate of (32.0%), compared to income tax expense of $9.7 million, for an effective tax rate of 52.7% in the prior year quarter. For the six months ended March 31, 2016, the Company recorded an income tax benefit of $5.4 million, for an effective tax rate of (28.2%), compared to income tax expense of $7.1 million, for an effective tax rate of 45.8% in the prior year period. The change in the effective tax rate was primarily attributable to (1) an increase in the non-deductible health insurer fee, and (2) a decrease in net earnings from continuing operations, which altered the rate impact of non-deductible expenses, non-controlling interests, and state income taxes including the Texas margins tax.

7. COMMITMENTS AND CONTINGENCIES

Acute Care Revenue

The calculation of appropriate payments from the Medicare and Medicaid programs, including supplemental Medicaid reimbursement, as well as terms governing agreements with other third-party payors are complex and subject to interpretation. Final determination of amounts earned under the Medicare and Medicaid programs often occurs subsequent to the year in which services are rendered because of audits by the programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for adjustments that may result from such routine audits and appeals.

Professional, General and Workers’ Compensation Liability Risks

The Company is subject to claims and legal actions incidental to the Company’s business, including claims relating to patient treatment and personal injuries. To cover these types of claims and actions, the Company maintains professional and general liability insurance in excess of self-insured retentions through a commercial insurance carrier in amounts that the Company believes to be sufficient for its operations, although, potentially, some claims may exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is currently not a party to any proceedings that, in the Company’s opinion, would have a material adverse effect on the Company’s business, financial condition or results of operations. The Company expenses an estimate of the costs it expects to incur under the self-insured retention exposure for professional and general liability claims using historical claims data, demographic factors, severity factors, current incident logs and other actuarial analysis. At March 31, 2016 and September 30, 2015, the Company’s professional and general liability accrual for asserted and unasserted claims totaled $52.5 million and $52.7 million, respectively, with the current portion totaling $15.0 million at both periods. The semi-annual valuations from the Company’s independent actuary for professional and general liability losses resulted in a changes related to estimates for prior years that impacted professional and general liability expense with an increase of $11.9 million during the quarter and six months ended March 31, 2016, and a decrease of $4.1 million during the quarter and six months ended March 31, 2015.

The Company is subject to claims and legal actions in the ordinary course of business relative to workers’ compensation matters. To cover these types of claims, the Company maintains workers’ compensation insurance coverage with a self-insured retention. The Company accrues the costs of workers’ compensation claims based upon estimates derived from its claims experience.

Health Choice

Health Choice has entered into capitated contracts whereby the Plan provides healthcare services in exchange for fixed periodic and supplemental payments from AHCCCS, ADHS and CMS. These services are provided regardless of the actual costs incurred to provide these services. The Plan receives reinsurance and other supplemental payments from AHCCCS to cover certain costs of healthcare services that exceed certain thresholds. The Company believes the capitated payments, together with reinsurance and other supplemental payments are sufficient to pay for the services Health Choice is obligated to deliver. As of March 31, 2016, the Company has provided performance guaranties in the form of a letter of credit totaling $60.0 million for the benefit of AHCCCS, a surety bond for the benefit of ADHS totaling $20.8 million and a demand note totaling $12.0 million for the benefit of CMS to support its obligations under the Health Choice contracts to provide and pay for the related healthcare services. The amount of these performance guaranties are generally based in part upon the membership in the Plan and the related capitation revenue paid to Health Choice.

Acquisitions

The Company has acquired and in the future may choose to acquire businesses with prior operating histories. Such businesses may have unknown or contingent liabilities, including liabilities for failure to comply with healthcare laws and regulations, such as billing and reimbursement, fraud and abuse and similar anti-referral laws. Although the Company has procedures designed to conform

 

16


Table of Contents

business practices to its policies following the completion of any acquisition, there can be no assurance that the Company will not become liable for previous activities of prior owners that may later be asserted to be improper by private plaintiffs or government agencies. Although the Company generally seeks to obtain indemnification from prospective sellers covering such matters, there can be no assurance that any such matter will be covered by indemnification, or if covered, that such indemnification will be adequate to cover potential losses and fines.

Other

On January 14, 2016, CMS entered into a Systems Improvement Agreement (“SIA”), with the Company’s Houston hospital, St. Joseph Medical Center (“SJMC”). CMS agreed to stay the scheduled termination of SJMC’s Medicare Provider Agreement during the pendency of the SIA, an action which resulted from surveys of the hospital that identified alleged failures to comply with certain Medicare program conditions of participation. As required by the terms of the SIA, the Company has retained an independent consultant to conduct a comprehensive review, including analysis of the hospital’s current operations, and develop a remediation plan. The SIA is scheduled to expire 18 months after its effective date, following an on-site survey by CMS, provided that SJMC demonstrates compliance with the Medicare conditions of participation for hospitals.

 

17


Table of Contents

8. SEGMENT INFORMATION

The Company’s reportable operating segments consist of (1) acute care hospitals and related healthcare businesses, collectively and (2) Health Choice. The following is a financial summary by business segment for the periods indicated (in thousands):

 

     For the Quarter Ended March 31, 2016  
     Acute Care      Health Choice      Eliminations      Consolidated  

Acute care revenue before provision for bad debts

   $ 598,194       $ —         $ —         $ 598,194   

Less: Provision for bad debts

     (98,881      —           —           (98,881
  

 

 

    

 

 

    

 

 

    

 

 

 

Acute care revenue

     499,313         —           —           499,313   

Premium, service and other revenue

     —           321,974         —           321,974   

Revenue between segments

     4,499         —           (4,499      —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue

     503,812         321,974         (4,499      821,287   

Salaries and benefits (excludes stock-based compensation)

     232,018         18,514         —           250,532   

Supplies

     83,864         249         —           84,113   

Medical claims

     —           272,529         (4,499      268,030   

Rentals and leases

     20,995         973         —           21,968   

Other operating expenses

     130,623         17,514         —           148,137   

Medicare and Medicaid EHR incentives

     (48      —           —           (48
  

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted EBITDA(1)

     36,360         12,195         —           48,555   

Interest expense, net

     34,033         —           —           34,033   

Depreciation and amortization

     25,706         1,351         —           27,057   

Stock-based compensation

     1,737         —           —           1,737   

Management fees

     1,250         —           —           1,250   
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from continuing operations before gain on disposal of assets and income taxes

     (26,366      10,844         —           (15,522

Gain on disposal of assets, net

     237         —           —           237   
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from continuing operations before income taxes

   $ (26,129    $ 10,844       $ —         $ (15,285
  

 

 

    

 

 

    

 

 

    

 

 

 

 

18


Table of Contents
     For the Quarter Ended March 31, 2015  
     Acute Care      Health Choice      Eliminations      Consolidated  

Acute care revenue before provision for bad debts

   $ 551,590       $ —         $ —         $ 551,590   

Less: Provision for bad debts

     (80,726      —           —           (80,726
  

 

 

    

 

 

    

 

 

    

 

 

 

Acute care revenue

     470,864         —           —           470,864   

Premium, service and other revenue

     —           225,963         —           225,963   

Revenue between segments

     3,894         —           (3,894      —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue

     474,758         225,963         (3,894      696,827   

Salaries and benefits (excludes stock-based compensation)

     221,051         14,376         —           235,427   

Supplies

     79,993         147         —           80,140   

Medical claims

     —           179,953         (3,894      176,059   

Rentals and leases

     18,391         697         —           19,088   

Other operating expenses

     96,680         17,066         —           113,746   

Medicare and Medicaid EHR incentives

     (2,235      —           —           (2,235
  

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted EBITDA(1)

     60,878         13,724         —           74,602   

Interest expense, net

     31,854         —           —           31,854   

Depreciation and amortization

     20,481         1,074         —           21,555   

Stock-based compensation

     1,841         —           —           1,841   

Management fees

     1,250         —           —           1,250   
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings from continuing operations before gain on disposal of assets and income taxes

     5,452         12,650         —           18,102   

Gain on disposal of assets, net

     394         —           —           394   
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings from continuing operations before income taxes

   $ 5,846       $ 12,650       $ —         $ 18,496   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

19


Table of Contents
     For the Six Months Ended March 31, 2016  
     Acute Care      Health Choice      Eliminations      Consolidated  

Acute care revenue before provision for bad debts

   $ 1,179,595       $ —         $ —         $ 1,179,595   

Less: Provision for bad debts

     (190,696      —           —           (190,696
  

 

 

    

 

 

    

 

 

    

 

 

 

Acute care revenue

     988,899         —           —           988,899   

Premium, service and other revenue

     —           635,236         —           635,236   

Revenue between segments

     8,458         —           (8,458      —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue

     997,357         635,236         (8,458      1,624,135   

Salaries and benefits (excludes stock-based compensation)

     458,366         35,417         —           493,783   

Supplies

     168,337         627         —           168,964   

Medical claims

     —           543,195         (8,458      534,737   

Rentals and leases

     41,369         1,931         —           43,300   

Other operating expenses

     242,802         35,085         —           277,887   

Medicare and Medicaid EHR incentives

     (490      —           —           (490
  

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted EBITDA(1)

     86,973         18,981         —           105,954   

Interest expense, net

     66,643         —           —           66,643   

Depreciation and amortization

     50,735         2,515         —           53,250   

Stock-based compensation

     3,344         —           —           3,344   

Management fees

     2,500         —           —           2,500   
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from continuing operations before gain on disposal of assets and income taxes

     (36,249      16,466         —           (19,783

Gain on disposal of assets, net

     725         —           —           725   
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings (loss) from continuing operations before income taxes

   $ (35,524    $ 16,466       $ —         $ (19,058
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment assets

   $ 2,310,669       $ 461,342          $ 2,772,011   
  

 

 

    

 

 

       

 

 

 

Capital expenditures

   $ 61,585       $ 465          $ 62,050   
  

 

 

    

 

 

       

 

 

 

Goodwill

   $ 815,582       $ 5,757          $ 821,339   
  

 

 

    

 

 

       

 

 

 

 

20


Table of Contents
     For the Six Months Ended March 31, 2015  
     Acute Care      Health Choice      Eliminations      Consolidated  

Acute care revenue before provision for bad debts

   $ 1,105,506       $ —         $ —         $ 1,105,506   

Less: Provision for bad debts

     (170,078      —           —           (170,078
  

 

 

    

 

 

    

 

 

    

 

 

 

Acute care revenue

     935,428         —           —           935,428   

Premium, service and other revenue

     —           430,937         —           430,937   

Revenue between segments

     7,836         —           (7,836      —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenue

     943,264         430,937         (7,836      1,366,365   

Salaries and benefits (excludes stock-based compensation)

     437,460         27,033         —           464,493   

Supplies

     159,889         302         —           160,191   

Medical claims

     —           359,867         (7,836      352,031   

Rentals and leases

     36,357         1,440         —           37,797   

Other operating expenses

     196,938         30,029         —           226,967   

Medicare and Medicaid EHR incentives

     (5,650      —           —           (5,650
  

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted EBITDA(1)

     118,270         12,266         —           130,536   

Interest expense, net

     64,217         —           —           64,217   

Depreciation and amortization

     42,084         2,102         —           44,186   

Stock-based compensation

     3,706         —           —           3,706   

Management fees

     2,500         —           —           2,500   
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings from continuing operations before loss on disposal of assets and income taxes

     5,763         10,164         —           15,927   

Loss on disposal of assets, net

     (454      —           —           (454
  

 

 

    

 

 

    

 

 

    

 

 

 

Earnings from continuing operations before income taxes

   $ 5,309       $ 10,164       $ —         $ 15,473   
  

 

 

    

 

 

    

 

 

    

 

 

 

Segment assets

   $ 2,327,624       $ 387,090          $ 2,714,714   
  

 

 

    

 

 

       

 

 

 

Capital expenditures

   $ 54,639       $ 1,642          $ 56,281   
  

 

 

    

 

 

       

 

 

 

Goodwill

   $ 812,176       $ 5,757          $ 817,933   
  

 

 

    

 

 

       

 

 

 

 

(1) Adjusted EBITDA represents net earnings (loss) from continuing operations before net interest expense, income tax expense (benefit), depreciation and amortization, stock-based compensation, gain (loss) on disposal of assets and management fees. Management fees represent monitoring and advisory fees paid to management companies affiliated with TPG and JLL. Management routinely calculates and communicates adjusted EBITDA and believes that it is useful to investors because it is commonly used as an analytical indicator within the healthcare industry to evaluate performance, allocate resources and measure leverage capacity and debt service ability. In addition, the Company uses adjusted EBITDA as a measure of performance for its business segments and for incentive compensation purposes. Adjusted EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to net earnings, cash flows generated by operating, investing, or financing activities or other financial statement data presented in the unaudited condensed consolidated financial statements as an indicator of financial performance or liquidity. Adjusted EBITDA, as presented, differs from “adjusted EBITDA” as defined under the Company’s Senior Secured Credit Facilities and may not be comparable to similarly titled measures of other companies.

 

21


Table of Contents

9. SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION

The Senior Notes described in Note 3 are fully and unconditionally guaranteed on a joint and several basis by all of the Company’s existing 100% owned existing domestic subsidiaries, other than certain non-guarantor subsidiaries, which include Health Choice. In addition, the Senior Notes are not guaranteed by the Company’s non-wholly owned subsidiaries. The guarantees are subject to customary release provisions set forth in the Indenture for the Senior Notes.

Summarized condensed consolidating balance sheets at March 31, 2016 and September 30, 2015, condensed consolidating statements of operations for the quarters and six months ended March 31, 2016 and 2015, condensed consolidating statements of comprehensive income (loss) for the quarters and six months ended March 31, 2016 and 2015, and condensed consolidating statements of cash flows for the six months ended March 31, 2016 and 2015, for the Company, segregating the parent company issuer, the subsidiary guarantors, the subsidiary non-guarantors and eliminations, are found below.

 

22


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Balance Sheet

March 31, 2016 (unaudited)

(In thousands)

 

            Subsidiary     Subsidiary            Condensed  
     Parent Issuer      Guarantors     Non-Guarantors      Eliminations     Consolidated  
Assets             

Current assets

            

Cash and cash equivalents

   $ —         $ 285,053      $ 82,494       $ —        $ 367,547   

Accounts receivable, net

     —           62,268        280,145         —          342,413   

Inventories

     —           15,246        48,363         —          63,609   

Prepaid expenses and other current assets

     —           43,292        123,976         —          167,268   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total current assets

     —           405,859        534,978         —          940,837   

Property and equipment, net

     —           306,468        624,450         —          930,918   

Intercompany

     —           (231,327     231,327         —          —     

Net investment in and advances to subsidiaries

     2,022,076         —          —           (2,022,076     —     

Goodwill

     7,407         83,755        730,177         —          821,339   

Other intangible assets, net

     —           7,711        10,500         —          18,211   

Other assets, net

     18,690         27,610        14,406         —          60,706   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total assets

   $ 2,048,173       $ 600,076      $ 2,145,838       $ (2,022,076   $ 2,772,011   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Liabilities and Equity

            

Current liabilities

            

Accounts payable

   $ —         $ 42,084      $ 90,310       $ —        $ 132,394   

Salaries and benefits payable

     —           29,095        47,796         —          76,891   

Accrued interest payable

     27,715         (3,220     3,220         —          27,715   

Medical claims payable

     —           —          132,504         —          132,504   

Other accrued expenses and current liabilities

     —           52,745        58,345         —          111,090   

Current portion of long-term debt, capital leases and other long-term obligations

     10,071         13,886        29,140         (29,140     23,957   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total current liabilities

     37,786         134,590        361,315         (29,140     504,551   

Long-term debt, capital leases and other long-term obligations

     1,810,268         36,172        627,764         (627,764     1,846,440   

Deferred income taxes

     105,632         —          —           —          105,632   

Other long-term liabilities

     —           92,354        1,019         —          93,373   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total liabilities

     1,953,686         263,116        990,098         (656,904     2,549,996   

Non-controlling interests with redemption rights

     —           113,962        —           —          113,962   

Equity

            

Member’s equity

     94,487         214,606        1,150,566         (1,365,172     94,487   

Non-controlling interests

     —           8,392        5,174         —          13,566   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total equity

     94,487         222,998        1,155,740         (1,365,172     108,053   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total liabilities and equity

   $ 2,048,173       $ 600,076      $ 2,145,838       $ (2,022,076   $ 2,772,011   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

 

23


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Balance Sheet

September 30, 2015

(In thousands)

 

     Parent Issuer      Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
     Eliminations     Condensed
Consolidated
 
Assets             

Current assets

            

Cash and cash equivalents

   $ —        $ 340,052      $ 38,461       $ —       $ 378,513   

Accounts receivable, net

     —          55,370        262,359         —         317,729   

Inventories

     —          14,829        47,764         —         62,593   

Deferred income taxes

     2,645         —         —          —         2,645   

Prepaid expenses and other current assets

     —          48,914        151,641         —         200,555   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total current assets

     2,645         459,165        500,225         —         962,035   

Property and equipment, net

     —          258,788        635,978         —         894,766   

Intercompany

     —          (199,017     199,017         —         —    

Net investment in and advances to subsidiaries

     2,061,270         —         —          (2,061,270     —    

Goodwill

     7,407         66,566        747,366         —         821,339   

Other intangible assets, net

     —          7,896        12,000         —         19,896   

Other assets, net

     16,683         22,670        16,243         —         55,596   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total assets

   $ 2,088,005       $ 616,068      $ 2,110,829       $ (2,061,270   $ 2,753,632   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Liabilities and Equity

            

Current liabilities

            

Accounts payable

   $ —        $ 44,820      $ 86,332       $ —       $ 131,152   

Salaries and benefits payable

     —          36,858        43,975         —         80,833   

Accrued interest payable

     26,896         (3,223     3,223         —         26,896   

Medical claims payable

     —          —         104,296         —         104,296   

Other accrued expenses and current liabilities

     —          44,498        53,826         —         98,324   

Current portion of long-term debt, capital leases and other long-term obligations

     10,071         1,745        22,286         (22,286     11,816   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total current liabilities

     36,967         124,698        313,938         (22,286     453,317   

Long-term debt, capital leases and other long-term obligations

     1,814,714         28,000        631,663         (631,663     1,842,714   

Deferred income taxes

     118,477         —         —          —         118,477   

Other long-term liabilities

     —          94,526        1,027         —         95,553   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total liabilities

     1,970,158         247,224        946,628         (653,949     2,510,061   

Non-controlling interests with redemption rights

     —          114,922        —          —         114,922   

Equity

            

Member’s equity

     117,847         245,520        1,161,801         (1,407,321     117,847   

Non-controlling interests

     —          8,402        2,400         —         10,802   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total equity

     117,847         253,922        1,164,201         (1,407,321     128,649   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total liabilities and equity

   $ 2,088,005       $ 616,068      $ 2,110,829       $ (2,061,270   $ 2,753,632   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

 

24


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Operations

For the Quarter Ended March 31, 2016 (unaudited)

(In thousands)

 

           Subsidiary     Subsidiary           Condensed  
     Parent Issuer     Guarantors     Non-Guarantors     Eliminations     Consolidated  

Revenues

          

Acute care revenue before provision for bad debts

   $ —        $ 135,637      $ 467,056      $ (4,499   $ 598,194   

Less: Provision for bad debts

     —          (10,971     (87,910     —          (98,881
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

     —          124,666        379,146        (4,499     499,313   

Premium, service and other revenue

     —          —          321,974        —          321,974   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     —          124,666        701,120        (4,499     821,287   

Costs and expenses

          

Salaries and benefits

     1,737        80,630        169,902        —          252,269   

Supplies

     —          20,856        63,257        —          84,113   

Medical claims

     —          —          272,529        (4,499     268,030   

Rentals and leases

     —          5,423        16,545        —          21,968   

Other operating expenses

     —          39,752        108,385        —          148,137   

Medicare and Medicaid EHR incentives

     —          (433     385        —          (48

Interest expense, net

     34,033        —          12,306        (12,306     34,033   

Depreciation and amortization

     —          9,820        17,237        —          27,057   

Management fees

     1,250        (7,736     7,736        —          1,250   

Equity in earnings of affiliates

     (7,097     —          —          7,097        —     
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

     29,923        148,312        668,282        (9,708     836,809   

Earnings (loss) from continuing operations before gain (loss) on disposal of assets and income taxes

     (29,923     (23,646     32,838        5,209        (15,522

Gain (loss) on disposal of assets, net

     —          (95     332        —          237   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

     (29,923     (23,741     33,170        5,209        (15,285

Income tax benefit

     (4,885     —          —          —          (4,885
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) from continuing operations

     (25,038     (23,741     33,170        5,209        (10,400

Earnings (loss) from discontinued operations, net of income taxes

     (103     270        —          —          167   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss)

     (25,141     (23,471     33,170        5,209        (10,233

Net earnings attributable to non-controlling interests

     —          (2,602     —          —          (2,602
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) attributable to IASIS Healthcare LLC

   $ (25,141   $ (26,073   $ 33,170      $ 5,209      $ (12,835
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

25


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Operations

For the Quarter Ended March 31, 2015 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
    Eliminations     Condensed
Consolidated
 

Revenues

          

Acute care revenue before provision for bad debts

   $ —       $ 127,899      $ 427,585      $ (3,894   $ 551,590   

Less: Provision for bad debts

     —         (8,722     (72,004     —         (80,726
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

     —         119,177        355,581        (3,894     470,864   

Premium, service and other revenue

     —         —         225,963        —         225,963   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     —         119,177        581,544        (3,894     696,827   

Costs and expenses

          

Salaries and benefits

     1,841        80,138        155,289        —         237,268   

Supplies

     —         18,788        61,352        —         80,140   

Medical claims

     —         —         179,953        (3,894     176,059   

Rentals and leases

     —         6,163        12,925        —         19,088   

Other operating expenses

     —         21,752        91,994        —         113,746   

Medicare and Medicaid EHR incentives

     —         (1,284     (951     —         (2,235

Interest expense, net

     31,854        —         11,973        (11,973     31,854   

Depreciation and amortization

     —         6,522        15,033        —         21,555   

Management fees

     1,250        (8,981     8,981        —         1,250   

Equity in earnings of affiliates

     (33,989     —         —         33,989        —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

     956        123,098        536,549        18,122        678,725   

Earnings (loss) from continuing operations before gain on disposal of assets and income taxes

     (956     (3,921     44,995        (22,016     18,102   

Gain on disposal of assets, net

     —         247        147        —         394   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

     (956     (3,674     45,142        (22,016     18,496   

Income tax expense

     9,747        —         —         —         9,747   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) from continuing operations

     (10,703     (3,674     45,142        (22,016     8,749   

Earnings (loss) from discontinued operations, net of income taxes

     2,910        (4,716     —         —         (1,806
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss)

     (7,793     (8,390     45,142        (22,016     6,943   

Net earnings attributable to non-controlling interests

     —         (2,763     —         —         (2,763
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) attributable to IASIS Healthcare LLC

   $ (7,793   $ (11,153   $ 45,142      $ (22,016   $ 4,180   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

26


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Operations

For the Six Months Ended March 31, 2016 (unaudited)

(In thousands)

 

           Subsidiary     Subsidiary           Condensed  
     Parent Issuer     Guarantors     Non-Guarantors     Eliminations     Consolidated  

Revenues

          

Acute care revenue before provision for bad debts

   $ —        $ 266,208      $ 921,845      $ (8,458   $ 1,179,595   

Less: Provision for bad debts

     —          (25,689     (165,007     —          (190,696
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

     —          240,519        756,838        (8,458     988,899   

Premium, service and other revenue

     —          —          635,236        —          635,236   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues

     —          240,519        1,392,074        (8,458     1,624,135   

Costs and expenses

          

Salaries and benefits

     3,344        160,163        333,620        —          497,127   

Supplies

     —          41,712        127,252        —          168,964   

Medical claims

     —          —          543,195        (8,458     534,737   

Rentals and leases

     —          10,534        32,766        —          43,300   

Other operating expenses

     —          63,226        214,661        —          277,887   

Medicare and Medicaid EHR incentives

     —          (499     9        —          (490

Interest expense, net

     66,643        —          22,586        (22,586     66,643   

Depreciation and amortization

     —          19,348        33,902        —          53,250   

Management fees

     2,500        (15,698     15,698        —          2,500   

Equity in earnings of affiliates

     (17,672     —          —          17,672        —     
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

     54,815        278,786        1,323,689        (13,372     1,643,918   

Earnings (loss) from continuing operations before gain on disposal of assets and income taxes

     (54,815     (38,267     68,385        4,914        (19,783

Gain on disposal of assets, net

     —          358        367        —          725   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

     (54,815     (37,909     68,752        4,914        (19,058

Income tax expense (benefit)

     (7,163     —          1,786        —          (5,377
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) from continuing operations

     (47,652     (37,909     66,966        4,914        (13,681

Earnings (loss) from discontinued operations, net of income taxes

     2,096        (5,982     —          —          (3,886
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss)

     (45,556     (43,891     66,966        4,914        (17,567

Net earnings attributable to non-controlling interests

     —          (5,403     —          —          (5,403
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) attributable to IASIS Healthcare LLC

   $ (45,556   $ (49,294   $ 66,966      $ 4,914      $ (22,970
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

27


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Operations

For the Six Months Ended March 31, 2015 (unaudited)

(in thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
    Eliminations     Condensed
Consolidated
 

Revenues

          

Acute care revenue before provision for bad debts

   $ —       $ 254,757      $ 858,585      $ (7,836   $ 1,105,506   

Less: Provision for bad debts

     —         (24,128     (145,950     —         (170,078
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

     —         230,629        712,635        (7,836     935,428   

Premium, service and other revenue

     —         —         430,937        —         430,937   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     —         230,629        1,143,572        (7,836     1,366,365   

Costs and expenses

          

Salaries and benefits

     3,706        159,074        305,419        —         468,199   

Supplies

     —         37,811        122,380        —         160,191   

Medical claims

     —         —         359,867        (7,836     352,031   

Rentals and leases

     —         12,336        25,461        —         37,797   

Other operating expenses

     —         39,339        187,628        —         226,967   

Medicare and Medicaid EHR incentives

     —         (1,464     (4,186     —         (5,650

Interest expense, net

     64,217        —         24,222        (24,222     64,217   

Depreciation and amortization

     —         14,413        29,773        —         44,186   

Management fees

     2,500        (17,947     17,947        —         2,500   

Equity in earnings of affiliates

     (49,751     —         —         49,751        —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

     20,672        243,562        1,068,511        17,693        1,350,438   

Earnings (loss) from continuing operations before gain (loss) on disposal of assets and income taxes

     (20,672     (12,933     75,061        (25,529     15,927   

Gain (loss) on disposal of assets, net

     —         (526     72        —         (454
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

     (20,672     (13,459     75,133        (25,529     15,473   

Income tax expense

     7,093        —         —         —         7,093   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) from continuing operations

     (27,765     (13,459     75,133        (25,529     8,380   

Earnings (loss) from discontinued operations, net of income taxes

     3,567        (6,873     —         —         (3,306
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss)

     (24,198     (20,332     75,133        (25,529     5,074   

Net earnings attributable to non-controlling interests

     —         (5,050     —         —         (5,050
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) attributable to IASIS Healthcare LLC

   $ (24,198   $ (25,382   $ 75,133      $ (25,529   $ 24   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

28


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Comprehensive Income (Loss)

For the Quarter Ended March 31, 2016 (unaudited)

(In thousands)

 

           Subsidiary     Subsidiary             Condensed  
     Parent Issuer     Guarantors     Non-Guarantors      Eliminations      Consolidated  

Net earnings (loss)

   $ (25,141   $ (23,471   $ 33,170       $ 5,209       $ (10,233

Other comprehensive income

            

Change in fair value of highly effective interest rate hedges

     487        —          —           —           487   
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Other comprehensive income before income taxes

     487        —          —           —           487   

Change in income tax expense

     (178     —          —           —           (178
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Other comprehensive income, net of income taxes

     309        —          —           —           309   
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Comprehensive income (loss)

     (24,832     (23,471     33,170         5,209         (9,924

Net earnings attributable to non-controlling interests

     —          (2,602     —           —           (2,602
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Comprehensive income (loss) attributable to IASIS Healthcare LLC

   $ (24,832   $ (26,073   $ 33,170       $ 5,209       $ (12,526
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

 

29


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Comprehensive Income (Loss)

For the Quarter Ended March 31, 2015 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
     Eliminations     Condensed
Consolidated
 

Net earnings (loss)

   $ (7,793   $ (8,390   $ 45,142       $ (22,016   $ 6,943   

Other comprehensive income

           

Change in fair value of highly effective interest rate hedges

     339        —         —          —         339   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Other comprehensive income before income taxes

     339        —         —          —         339   

Change in income tax expense

     (124     —         —          —         (124
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Other comprehensive income, net of income taxes

     215        —         —          —         215   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Comprehensive income (loss)

     (7,578     (8,390     45,142         (22,016     7,158   

Net earnings attributable to non-controlling interests

     —         (2,763     —          —         (2,763
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Comprehensive income (loss) attributable to IASIS Healthcare LLC

   $ (7,578   $ (11,153   $ 45,142       $ (22,016   $ 4,395   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

 

30


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Comprehensive Income (Loss)

For the Six Months Ended March 31, 2016 (unaudited)

(In thousands)

 

           Subsidiary     Subsidiary             Condensed  
     Parent Issuer     Guarantors     Non-Guarantors      Eliminations      Consolidated  

Net earnings (loss)

   $ (45,556   $ (43,891   $ 66,966       $ 4,914       $ (17,567

Other comprehensive income

            

Change in fair value of highly effective interest rate hedges

     976        —          —           —           976   
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Other comprehensive income before income taxes

     976        —          —           —           976   

Change in income tax expense

     (356     —          —           —           (356
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Other comprehensive income, net of income taxes

     620        —          —           —           620   
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Comprehensive income (loss)

     (44,936     (43,891     66,966         4,914         (16,947

Net earnings attributable to non-controlling interests

     —          (5,403     —           —           (5,403
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

Comprehensive income (loss) attributable to IASIS Healthcare LLC

   $ (44,936   $ (49,294   $ 66,966       $ 4,914       $ (22,350
  

 

 

   

 

 

   

 

 

    

 

 

    

 

 

 

 

31


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Comprehensive Income (Loss)

For the Six Months Ended March 31, 2015 (unaudited)

(In thousands)

 

     Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
     Eliminations     Condensed
Consolidated
 

Net earnings (loss)

   $ (24,198   $ (20,332   $ 75,133       $ (25,529   $ 5,074   

Other comprehensive income

           

Change in fair value of highly effective interest rate hedges

     745        —         —          —         745   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Other comprehensive income before income taxes

     745        —         —          —         745   

Change in income tax expense

     (273     —         —          —         (273
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Other comprehensive income, net of income taxes

     472        —         —          —         472   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Comprehensive income (loss)

     (23,726     (20,332     75,133         (25,529     5,546   

Net earnings attributable to non-controlling interests

     —         (5,050     —          —         (5,050
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Comprehensive income (loss) attributable to IASIS Healthcare LLC

   $ (23,726   $ (25,382   $ 75,133       $ (25,529   $ 496   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

 

32


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Cash Flows

For the Six Months Ended March 31, 2016 (unaudited)

(In thousands)

 

          Subsidiary     Subsidiary           Condensed  
    Parent Issuer     Guarantors     Non-Guarantors     Eliminations     Consolidated  

Cash flows from operating activities

         

Net earnings (loss)

  $ (45,556   $ (43,891   $ 66,966      $ 4,914      $ (17,567

Adjustments to reconcile net earnings (loss) to net cash provided by (used in) operating activities:

         

Depreciation and amortization

    —          19,348        33,902        —          53,250   

Amortization of loan costs

    4,012        —          —          —          4,012   

Amortization of deferred gain on sale-leaseback transaction

    (1,248     —          —          —          (1,248

Change in physician minimum revenue guarantees

    —          50        2,000        —          2,050   

Stock-based compensation

    3,344        —          —          —          3,344   

Deferred income taxes

    (8,512     —          —          —          (8,512

Gain on disposal of assets, net

    —          (358     (367     —          (725

Loss (earnings) from discontinued operations, net

    (2,096     5,982        —          —          3,886   

Equity in earnings of affiliates

    (17,672     —          —          17,672        —     

Changes in operating assets and liabilities, net of the effect of acquisitions and dispositions:

         

Accounts receivable, net

    —          (6,899     (17,785     —          (24,684

Inventories, prepaid expenses and other current assets

    —          3,012        27,079        —          30,091   

Accounts payable, other accrued expenses and other accrued liabilities

    (1,151     1,238        34,068        —          34,155   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) operating activities — continuing operations

    (68,879     (21,518     145,863        22,586        78,052   

Net cash provided by operating activities — discontinued operations

    —          637        —          —          637   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) operating activities

    (68,879     (20,881     145,863        22,586        78,689   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash flows from investing activities

         

Purchases of property and equipment

    —          (40,214     (21,836     —          (62,050

Cash paid for acquisitions, net

    —          —          (2,311     —          (2,311

Cash paid related to divestiture

    —          (5,869     —          —          (5,869

Proceeds from sale of assets

    —          121        45        —          166   

Change in other assets, net

    —          (1,434     1,833        —          399   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in investing activities

    —          (47,396     (22,269     —          (69,665
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash flows from financing activities

         

Payment of long-term debt, capital leases and other long-term obligations

    (7,232     (364     (692     —          (8,288

Payment of debt financing costs

    (5,179     —          —          —          (5,179

Distributions to non-controlling interests

    —          —          (5,563     —          (5,563

Cash paid for the repurchase of non-controlling interests

    —          —          (960     —          (960

Change in intercompany balances with affiliates, net

    81,290        13,642        (72,346     (22,586     —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) financing activities

    68,879        13,278        (79,561     (22,586     (19,990
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Change in cash and cash equivalents

    —          (54,999     44,033        —          (10,966

Cash and cash equivalents at beginning of period

    —          340,052        38,461        —          378,513   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at end of period

  $ —        $ 285,053      $ 82,494      $ —        $ 367,547   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

33


Table of Contents

IASIS Healthcare LLC

Condensed Consolidating Statement of Cash Flows

For the Six Months Ended March 31, 2015 (unaudited)

(In thousands)

 

    Parent Issuer     Subsidiary
Guarantors
    Subsidiary
Non-Guarantors
    Eliminations     Condensed
Consolidated
 

Cash flows from operating activities

         

Net earnings (loss)

  $ (24,198   $ (20,332   $ 75,133      $ (25,529   $ 5,074   

Adjustments to reconcile net earnings (loss) to net cash provided by (used in) operating activities:

         

Depreciation and amortization

    —         14,413        29,773        —         44,186   

Amortization of loan costs

    3,942        —         —         —         3,942   

Amortization of deferred gain on sale-leaseback transaction

    (1,248     —         —         —         (1,248

Change in physician minimum revenue guarantees

    —         103        1,768        —         1,871   

Stock-based compensation

    3,706        —         —         —         3,706   

Deferred income taxes

    7,967        —         —         —         7,967   

Loss (gain) on disposal of assets, net

    —         526        (72     —         454   

Loss (earnings) from discontinued operations, net

    (3,567     6,873        —         —         3,306   

Equity in earnings of affiliates

    (49,751     —         —         49,751        —    

Changes in operating assets and liabilities, net of the effect of acquisitions and dispositions:

         

Accounts receivable, net

    —         (2,752     (24,571     —         (27,323

Inventories, prepaid expenses and other current assets

    —         (31,342     (11,273     —         (42,615

Accounts payable, other accrued expenses and other accrued liabilities

    (1,108     1,984        17,747        —         18,623   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) operating activities — continuing operations

    (64,257     (30,527     88,505        24,222        17,943   

Net cash used in operating activities — discontinued operations

    —         (755     —         —         (755
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) operating activities

    (64,257     (31,282     88,505        24,222        17,188   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash flows from investing activities

         

Purchases of property and equipment

    —         (35,810     (20,471     —         (56,281

Cash paid for acquisitions, net

    —         —           (3,900     —         (3,900

Cash received related to divestiture

    —         41,364        —         —         41,364   

Proceeds from sale of assets

    —         256        81        —         337   

Change in other assets, net

    —         (1,662     865        —         (797
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) investing activities — continuing operations

    —         4,148        (23,425     —         (19,277

Net cash used in investing activities — discontinued operations

    —         (341     —         —         (341
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) investing activities

    —         3,807        (23,425     —         (19,618
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash flows from financing activities

         

Payment of long-term debt, capital leases and other long-term obligations

    (5,135     (311     (1,262     —         (6,708

Distributions to non-controlling interests

    —         (4,438     —         —         (4,438

Cash paid for the repurchase of non-controlling interests

    —         (558     (460     —         (1,018

Change in intercompany balances with affiliates, net

    69,392        9,995        (55,165     (24,222     —    
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) financing activities — continuing operations

    64,257        4,688        (56,887     (24,222     (12,164

Net cash used in financing activities — discontinued operations

    —         (6     —         —         (6
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) financing activities

    64,257        4,682        (56,887     (24,222     (12,170
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Change in cash and cash equivalents

    —         (22,793     8,193        —         (14,600

Cash and cash equivalents at beginning of period

    —         325,555        15,625        —         341,180   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at end of period

  $ —       $ 302,762      $ 23,818      $ —       $ 326,580   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

34


Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements, the notes to our unaudited condensed consolidated financial statements and the other financial information appearing elsewhere in this Quarterly Report on Form 10-Q (this “Report”). Data for the quarters and six months ended March 31, 2016 and 2015, have been derived from our unaudited condensed consolidated financial statements. In this Report, unless otherwise stated or indicated by context, references to the “Company,” “IASIS,” “we,” “our” or “us” refer to IASIS Healthcare LLC and its affiliates. Unless the context otherwise implies, the term “affiliates” means direct and indirect subsidiaries of IASIS Healthcare LLC and partnerships and joint ventures in which such subsidiaries are partners. The terms “facilities” or “hospitals” refer to entities owned and operated by affiliates of IASIS and the term “employees” refers to employees of affiliates of IASIS. References herein to “IAS” are to IASIS Healthcare Corporation, our parent company.

FORWARD-LOOKING STATEMENTS

Our disclosure and analysis in this Report contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which involve risks and uncertainties. Forward-looking statements include all statements that do not relate solely to historical or current facts, and you can identify forward-looking statements because they contain words such as “believes,” “expects,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates,” “projects,” “continue,” “initiative,” or “anticipates” or similar expressions that concern our prospects, objectives, strategies, plans or intentions. These forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, our actual results may differ materially from those expected. While we believe our assumptions are reasonable, these assumptions are inherently subject to significant regulatory, economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. These factors include, but are not limited to:

 

    the effects of changes in governmental healthcare programs, principally Medicare, Medicaid and other federal healthcare programs and Medicaid supplemental or waiver programs, including limitations or reductions of levels of payments that our hospitals receive under such programs;

 

    the effects related to implementation or possible amendment of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Health Reform Law”), the possible enactment of additional federal or state healthcare reforms and the outcome of court challenges to such laws and other federal, state or local laws or regulations affecting the healthcare industry;

 

    the ability of Health Choice Arizona, Inc. and related entities (“Health Choice” or the “Plan”), our managed care business, to effectively manage costs of care, maintain its governmental contracts and achieve its service line expansion strategies;

 

    the effects of a shift in volume or payor mix from commercial managed care payors to self-pay and Medicaid;

 

    increases in the amount, and risk of collectability, of uninsured accounts and deductibles and copayment amounts for insured accounts;

 

    a reduction in or withholding of government-sponsored supplemental payments to our hospitals;

 

    the effects of any inability to retain and negotiate reasonable contracts with managed care plans or if insured patients switch from traditional commercial insurance plans to health insurance exchange (“Exchange”) plans;

 

    consolidation among managed care organizations, which may reduce our ability to negotiate favorable contracts with such payors;

 

    industry trends towards value-based purchasing and narrow networks and related competitive challenges to our hospitals;

 

    controls imposed by Medicare and third-party payors to reduce admissions and length of stay, which negatively impact healthcare provider reimbursement;

 

    competition to attract and retain quality physicians, nurses, technicians and other personnel;

 

    the generally competitive nature of the healthcare industry;

 

    the possibility of health pandemics and the related impacts on our operations and financial results;

 

    a failure of our information systems or breach of our cybersecurity protections;

 

    the costs and operational challenges associated with information technology and medical equipment upgrades;

 

    challenges associated with the implementation of electronic health records (“EHRs”) and coding systems;

 

35


Table of Contents
    compliance with extensive healthcare industry laws, regulations and investigations, including those with respect to patient privacy and physician-owned hospitals;

 

    reliance upon services provided by third-party vendors;

 

    the effects of local or national economic downturns on our business lines;

 

    risks associated with our acquisition and development strategy, including liabilities assumed in acquisitions of facilities and physician practices and our need to effectively integrate acquired companies into our existing operations;

 

    increased lease rates and amended lease terms at certain of our facilities in connection with sale-leaseback transactions;

 

    risks associated with environmental, health and safety laws;

 

    risks associated with labor laws;

 

    potential adverse accounting impacts associated with goodwill carrying value;

 

    our dependence upon the services of key executive management personnel;

 

    our ability to maintain adequate internal controls over our financial and management systems;

 

    risks related to our indebtedness and capital structure; and

 

    other risk factors described in our Annual Report on Form 10-K for the fiscal year ended September 30, 2015, filed with the Securities and Exchange Commission (the “SEC”) on December 22, 2015 (our “2015 Form 10-K”), and in our other public filings with the SEC.

Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statement that we make in this Report speaks only as of the date of such statement, and we undertake no obligation to update any forward-looking statements or to publicly announce the results of any revisions to any of those statements to reflect future events or developments. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data.

EXECUTIVE OVERVIEW

We are a healthcare services company delivering high-quality, cost-effective healthcare through a broad and differentiated set of capabilities and assets that includes acute care hospitals with related patient access points, and a diversified and growing managed care risk platform (“risk platform”). Our business model is centered on deploying our acute care expertise and risk platform, either separately or on an integrated basis to manage population health, integrate the delivery and payment of healthcare services and ultimately expand our total market opportunities within our existing and new geographic markets. Our business consists of two operating segments: (i) our acute care operations, which, as of March 31, 2016, included 17 acute care hospitals, one behavioral hospital and multiple other access points, including 147 physician clinics, multiple outpatient surgical units, imaging centers, and investments in urgent care centers and on-site employer-based clinics, and (ii) our managed care operations, comprised of our diversified and growing risk platform, Health Choice, which operates managed Medicaid and Medicare health plans, an Exchange plan and a management services organization (“MSO”) that provides management and administrative services to third-party insurers, as well as accountable care networks in conjunction with our acute care facilities.

Acute Care Operations

As of March 31, 2016, we owned or leased 17 acute care hospital facilities and one behavioral health hospital facility with a total of 3,661 licensed beds, several outpatient service facilities and 147 physician clinics.

We operate our hospitals with a strong community focus by offering and developing healthcare services targeted to the needs of the markets we serve, promoting strong relationships with physicians and working with local managed care plans to develop quality and outcome driven, cost-efficient and innovative reimbursement models. Our major acute care geographic markets include Salt Lake City, Utah; Phoenix, Arizona; six cities in Texas, including Houston, San Antonio and Odessa; and West Monroe, Louisiana.

Since our Company was founded in 1998, we believe we have developed a reputation for operating hospitals that deliver high quality care in our markets at rates that are often more affordable than many other hospitals in our markets with larger local market share than us. Our corporate and divisional infrastructure allows us to leverage savings in information technology services, revenue cycle, hospital supplies, and labor force costs.

 

36


Table of Contents

Managed Care Operations

Health Choice, headquartered in Phoenix, Arizona, began providing managed Medicaid services under contract with the Arizona Health Care Cost Containment System (“AHCCCS”) in 1990, making it one of the nation’s first Medicaid managed care plans. Under our ownership beginning in 1999, Health Choice has evolved into a managed care organization and insurer which, while growing its core managed Medicaid business, has expanded to serve certain Medicare Advantage and Exchange members and is utilizing its population health management expertise to offer MSO-related services to other payors. In collaboration with our hospitals and affiliated physicians in certain of our markets, Health Choice also manages accountable care networks.

Health Choice represents one of our Company’s key strategic assets, which we believe provides the Company with the ability to engage in innovative value-based purchasing initiatives and opportunities. Its leadership team has considerable experience in population health management, physician relations and network development. We believe Health Choice also deploys state of the art disease management and claims processing technology. In light of the current healthcare industry trends toward integrated delivery and clinical integration, we are seeking to use Health Choice’s expertise and technology in the management of the accountable care networks we offer to other health plans.

Effective October 1, 2015, Health Choice’s joint venture, Health Choice Integrated Care LLC (“HCIC”) entered into a contract with the Arizona Department of Health Services (“ADHS”). The contract has an initial term of three years and includes two additional two-year renewal options that can be exercised at the discretion of ADHS. The contract is terminable by ADHS following HCIC’s failure to carry out a material contract term, condition or obligation.

As of March 31, 2016, Health Choice’s related entities managed healthcare services for 656,200 covered lives through multiple health plans, accountable care networks, MSO-related services and other managed care solutions. These include 264,000 managed Medicaid lives served primarily through Health Choice’s core health plan business in Arizona, 226,200 HCIC plan members, 9,600 Medicare Advantage members eligible for both Medicare and Medicaid (“Duals”), 12,800 Exchange lives, 96,600 MSO lives and 98,300 lives attributed to our accountable care networks from multiple payors whose care is managed by our network providers, of which 51,300 lives are included in Health Choice’s managed Medicaid and Exchange plans.

Recent Developments

Health Choice Integrated Behavioral Health Joint Venture. On October 1, 2015, Health Choice, together with the Northern Arizona Behavioral Health Authority (“NARBHA”), its joint venture partner, began operating an integrated acute and behavioral health plan in Northern Arizona. As of March 31, 2016, the joint venture, HCIC provided standalone behavioral health benefits for 226,200 plan members. We believe that, in the future, states other than Arizona may adopt this model of integration of acute and behavioral health benefits under one managed care organization, such as HCIC. Health Choice owns 52% of the joint venture and NARBHA owns the remaining 48%.

Regulatory Matter. On January 14, 2016, the Centers for Medicare and Medicaid Services (“CMS”) entered into a Systems Improvement Agreement (“SIA”), with our Houston hospital, St. Joseph Medical Center (“SJMC”). CMS agreed to stay the scheduled termination of SJMC’s Medicare Provider Agreement during the pendency of the SIA, an action which resulted from surveys of the hospital that identified alleged failures to comply with certain Medicare program conditions of participation. As required by the terms of the SIA, the Company has retained an independent consultant to conduct a comprehensive review, including analysis of the hospital’s current operations, and develop a remediation plan. The SIA is scheduled to expire 18 months after its effective date, following an on-site survey by CMS, provided that SJMC demonstrates compliance with the Medicare conditions of participation for hospitals.

 

37


Table of Contents

Revenue and Volume Trends

Total revenue for the quarter ended March 31, 2016, increased 17.9% to $821.3 million, compared to $696.8 million in the same prior year quarter. Total revenue for the six months ended March 31, 2016, increased 18.9% to $1.62 billion, compared to $1.37 billion in the same prior year period. Total revenue is comprised of acute care revenue, which is recorded net of the provision for bad debts, and premium, service and other revenue. Acute care revenue contributed $28.4 million to the increase in total revenue for the quarter ended March 31, 2016, compared to the same prior year quarter, while premium, service and other revenue of our risk platform contributed $96.0 million to the increase in total revenue compared to the same prior year quarter. Acute care revenue contributed $53.5 million to the increase in total revenue for the six months ended March 31, 2016, compared to the same prior year period, while premium, service and other revenue of our risk platform contributed $204.3 million to the increase in total revenue compared to the same prior year period.

Acute Care Revenue

Acute care revenue is comprised of net patient revenue and other revenue. A large percentage of our hospitals’ net patient revenue consists of fixed payment, discounted sources, including Medicare, Medicaid and managed care organizations. Reimbursement for Medicare and Medicaid services are often fixed regardless of the cost incurred or the level of services provided. Similarly, a greater percentage of the managed care companies we contract with reimburse providers on a fixed payment basis regardless of the costs incurred or the level of services provided. Net patient revenue is reported net of discounts and contractual adjustments. The contractual adjustments principally result from differences between the hospitals’ established charges and payment rates under Medicare, Medicaid and various managed care plans. Additionally, discounts and contractual adjustments result from our uninsured discount and charity care programs. Acute care revenue is reported net of the provision for bad debts. Other revenue includes medical office building rental income and other miscellaneous revenue.

For the quarter ended March 31, 2016, admissions increased 0.5% and adjusted admissions increased 2.1%, both compared to the same prior year quarter. Excluding volume at the Company’s Houston hospital, for the quarter ended March 31, 2016, admissions increased 1.9% and adjusted admissions increased 2.4%, both compared to the same prior year quarter. For the six months ended March 31, 2016, admissions decreased 0.5% and adjusted admissions increased 1.9%, both compared to the same prior year period. Excluding volume at the Company’s Houston hospital, for the six months ended March 31, 2016, admissions increased 1.5% and adjusted admissions increased 3.2%, both compared to the same prior year period. For the quarter ended March 31, 2016, our volumes also were impacted by an increase in emergency room visits of 1.3% and an increase in surgeries of 4.1%, both compared to the same prior year quarter. For the six months ended March 31, 2016, our volumes were impacted by an increase in emergency room visits of 0.2% and an increase in surgeries of 6.0%, both compared to the same prior year period.

The following table provides the sources of our hospitals’ gross patient revenue by payor before discounts, contractual adjustments and the provision for bad debt:

 

     Quarter Ended
March 31,
    Six Months Ended
March 31,
 
     2016     2015     2016     2015  

Medicare

     25.3     28.5     26.4     27.2

Managed Medicare

     15.3        15.4        15.6        15.1   

Medicaid and managed Medicaid

     21.5        20.9        21.2        21.5   

Managed care and other

     32.6        29.9        31.7        30.8   

Self-pay

     5.3        5.3        5.1        5.4   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total

     100.0     100.0     100.0     100.0
  

 

 

   

 

 

   

 

 

   

 

 

 

 

38


Table of Contents

The following table provides the sources of our hospitals’ net patient revenue by payor before the provision for bad debts:

 

     Quarter Ended
March 31,
    Six Months Ended
March 31,
 
     2016     2015     2016     2015  

Medicare

     18.2     20.5     18.9     19.8

Managed Medicare

     10.3        10.1        10.4        10.1   

Medicaid and managed Medicaid

     11.9        12.8        12.4        12.7   

Managed care and other

     44.3        41.3        43.4        41.9   

Self-pay

     15.3        15.3        14.9        15.5   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total

     100.0     100.0     100.0     100.0
  

 

 

   

 

 

   

 

 

   

 

 

 

Net patient revenue per adjusted admission, which includes the impact of the provision for bad debts, increased 3.6% for the quarter and six months ended March 31, 2016, both compared to the same prior year periods.

See “Item 1 — Business — Sources of Revenue — Acute Care Revenue” and “Item 1 — Business — Government Regulation and Other Factors” included in our 2015 Form 10-K for a description of the types of payments we receive for services provided to patients enrolled in the traditional Medicare plan, managed Medicare plans, Medicaid plans, managed Medicaid plans and managed care plans. In those sections, we also discussed the unique reimbursement features of the traditional Medicare plan, including the annual Medicare regulatory updates published by CMS that impact reimbursement rates for services provided under the plan. The future potential impact to reimbursement for certain of these payors under the Health Reform Law is also discussed in such Annual Report on Form 10-K.

Premium, Service and Other Revenue

Premium, service and other revenue generated by our managed care operations represented 39.2% and 39.1% of our total revenue for the quarter and six months ended March 31, 2016, respectively, compared to 32.4% and 31.5% in the same prior year periods. The increase in the percentage of revenue derived from our managed care operations was due primarily to a 75.3% increase in total lives served across all product lines, which included the addition of 226,200 new members served by HCIC, our joint venture providing behavioral health and integrated care benefits primarily to the people of Northern Arizona. In addition, lives in our Exchange plan increased to 12,800 at March 31, 2016, compared to 5,400 members at March 31, 2015.

Health Choice contracts with state Medicaid programs in Arizona and Utah to provide specified health services to qualified Medicaid enrollees through contracted healthcare providers. Most of its premium revenue is derived through a contract with AHCCCS, the state agency that administers Arizona’s Medicaid program. The contract requires Health Choice to arrange for healthcare services for enrolled Medicaid patients in exchange for fixed monthly premiums, based upon negotiated per capita member rates, and supplemental payments from AHCCCS. Premium revenue includes adjustments to revenue related to the program settlement process for the Arizona managed Medicaid plan under the related state contract. This program settlement process reconciles estimated amounts due to or from the state based on contractually mandated limits on profits and losses. Although estimates of future program settlement amounts are recorded in current periods, the program settlement process typically occurs 18 months post-plan year, when actual (rather than projected) claims and member eligibility data become available and a net settlement amount is either due to or from the state. Adjustments to the estimates of future program settlement amounts are recorded as a component of premium revenue. During the quarter and six months ended March 31, 2016, we recognized $0.6 million and $3.9 million, respectively, in reductions to premium revenue associated with the final settlement of certain amounts related to the 2014 contract year.

Health Choice also contracts with CMS to provide coverage as a Medicare Advantage Prescription Drug (“MAPD”) Special Needs Plan (“Plan”). This contract allows Health Choice to offer Medicare and Part D drug benefit coverage to new and existing dual-eligible members (i.e., those that are eligible for Medicare and Medicaid). In accordance with CMS regulations, SNPs are now expected to meet additional requirements, including requirements relating to model of care, cost-sharing, disclosure of information and reporting of quality measures.

One notable provision of the Health Reform Law is the annual health insurer fee (“HIF”) that applies to most health plans, including commercial health plans and Medicaid managed care plans like Health Choice. While characterized as a “fee” in the text of the Health Reform Law, the intent of Congress was to impose a broad based health insurance industry excise tax, with the understanding that the tax could be passed on to consumers, most likely through higher commercial insurance premiums. However, because Medicaid is a government-funded program, Medicaid health plans have no alternative but to look to their respective state partners for payment to offset the impact of this tax. Arizona has agreed to reimburse all of the managed Medicaid plans, for the economic impact of this fee. In addition to the reimbursement of the fee, the state of Arizona has agreed to reimburse insurers for the impact resulting from these fees being treated as non-deductible for income tax purposes. For the quarter and six months ended March 31, 2016, we recognized expense for the HIF totaling $4.0 million and $7.7 million, respectively, which was offset by expected reimbursement from the state of Arizona of $5.1 million and $10.0 million, respectively.

 

39


Table of Contents

Other Industry Items Impacting Our Company

The following section discusses updates to trends discussed in our 2015 Form 10-K that we believe are significant factors in our current and/or future operating results and cash flows. Certain of these trends apply to the entire acute care hospital industry, while others may apply to us more specifically. These trends could be short-term in nature or could require long-term attention and resources. While these trends may involve certain factors that are outside of our control, the extent to which these trends affect our hospitals and health plan operations and our ability to manage the impact of these trends play vital roles in our current and future success. In many cases, we are unable to predict what impact, if any, these trends will have on us.

State Medicaid Budgets

In recent years, the states in which we operate have experienced budget constraints as a result of increased costs and lower than expected tax collections. Health and human services programs, including Medicaid and similar programs, represent a significant portion of state budgets. The states in which we operate responded to these budget concerns by decreasing funding for Medicaid and other healthcare programs or by making structural changes that resulted in a reduction in hospital reimbursement, as well as by imposing more restrictive Medicaid eligibility requirements. In addition, many states have received waivers from CMS in order to implement or expand managed Medicaid programs.

Texas

Currently, Texas is operating under a five-year Medicaid Transformation Waiver that: (1) allows Texas to expand its Medicaid managed care program while preserving hospital funding; (2) provides incentive payments for improvements in healthcare delivery; and (3) directs more funding to hospitals that serve large numbers of uninsured patients. CMS has agreed to extend the Texas waiver program and maintain its current funding through December 2017. We cannot predict whether the Texas Medicaid waiver program will be further extended or continue in its current form, nor can we guarantee that revenues recognized from the program will not decrease.

All of our acute care hospitals in Texas currently receive supplemental Medicaid reimbursement, including reimbursement from programs for participating private hospitals that enter into indigent care affiliation agreements with public hospitals or county governments in the state of Texas. Under the CMS-approved programs, affiliated hospitals, including our Texas hospitals, have expanded the community healthcare safety net by providing indigent healthcare services. Revenue recognized under these Texas private supplemental Medicaid reimbursement programs, including amounts recognized under the Texas Medicaid Disproportionate Share Hospital program (“Texas Medicaid DSH”) for the quarters and six months ended March 31, 2016 and 2015, respectively, was $30.0 million and $58.5 million, respectively, compared to $26.8 million and $50.7 million in the same prior year periods. Under the Medicaid waiver, funds are distributed to participating hospitals based upon both the costs associated with providing care to individuals without third party coverage and the investment made to support coordinating care and quality improvements that transform the local communities’ care delivery systems. The responsibility to coordinate and develop plans that address the concerns of the local delivery care systems, including improved access, quality, cost effectiveness and coordination is controlled primarily by public hospitals or local government entities that serve the surrounding geographic areas. Complexities of the underlying methodologies in determining the funding for the state’s Medicaid supplemental reimbursement programs, along with a lack of sufficient resources at the Texas Health and Human Services Commission to administer the programs, resulted in a delay in related reimbursements. However, during 2016, timing of reimbursement under these programs has improved. As of March 31, 2016 and September 30, 2015, we had $50.0 million and $77.6 million, respectively, in receivables due to our Texas hospitals in connection with these supplemental reimbursement programs, which includes $4.5 million and $20.2 million, respectively, of amounts due under Texas Medicaid DSH.

 

40


Table of Contents

Arizona

Effective January 1, 2014, Arizona expanded its Medicaid program under the Health Reform Law, which includes increased eligibility for adults, children and pregnant women, and the restoration of eligibility to childless adults that had previously been eliminated. As a result of the Medicaid expansion and of the Plan’s increase in total coverage area under its most recent AHCCCS contract, enrollment under Health Choice’s Medicaid product line increased 13.5% for the quarter ended March 31, 2016, compared to the same prior year quarter. In addition, in connection with the expanded Medicaid coverage, the state implemented a provider assessment to fund a portion of the expanded eligibility related to the childless adult population. During the quarter and six months ended March 31, 2016, we incurred $2.1 million and $4.3 million, respectively, in provider fee assessments compared to $2.3 million and $4.3 million in the same prior year periods.

Further, while the Arizona Medicaid expansion became effective on January 1, 2014, a lawsuit filed by several state lawmakers has challenged the legality of a provider fee assessed to all providers and used to help pay for Arizona’s Medicaid expansion. On August 26, 2015, the Arizona State Superior Court upheld the legality of the provider fee, thus preserving the existing funding for Medicaid expansion in Arizona. The plaintiffs are appealing this decision. A successful appeal, invalidating the provider fee used to help fund Arizona’s Medicaid expansion, may result in the loss of certain funding for the state’s Medicaid program, which could potentially result in changes that restrict eligibility and increase the number of uninsured individuals, therefore, adversely affecting our operations in Arizona.

Arizona’s Medicaid expansion and Health Choice’s related increase in enrolled members and premium revenue, followed a period of several years during which AHCCCS tightened Medicaid eligibility standards in Arizona and decreased capitation rates paid to managed Medicaid contractors, reflecting state government budgetary pressures and a struggling state economy. While the expansion of Arizona’s Medicaid program has positively impacted both our acute and managed care operations, this has been partially mitigated by the cost associated with the provider fee assessments.

Uncompensated Care

While the overall amount of uncompensated care, including discounts to the uninsured, bad debts and charity care, we deliver to the communities we serve has declined since the implementation of the Health Reform Law, we have recently experienced increases in uncompensated care in the quarter and six months ended March 31, 2016, as a result of the factors set forth below. During the quarter and six months ended March 31, 2016, our uncompensated care as a percentage of acute care revenue was 20.8% and 20.5%, respectively, compared to 19.5% and 20.5% in the same prior year periods. We believe that the increase in uncompensated care during the quarter ended March 31, 2016, is due, in large part, to the growth of Exchange and managed care plans with higher deductibles and co-pays and the decrease in collections of such higher patient related balances. Additionally, while we continue to experience reductions in Medicare DSH reimbursement in connection with funding for the Health Reform Law, states such as Texas have not expanded coverage under its Medicaid program. As a result, we believe we will continue to experience higher levels of uncompensated care in our Texas Markets until the state implements meaningful Medicaid expansion. During the quarter ended March 31, 2016, our self-pay admissions represented 6.1% of our total admissions, compared to 5.9% in the same prior year quarter. During the six months ended March 31, 2016, our self-pay admissions represented 6.2% of our total admissions, compared to 6.0% in the same prior year period.

If we were to experience continued growth in uninsured and under-insured volume and revenue, our uncompensated care may continue to increase and our results of operations would continue to be adversely affected.

Two Midnight Rule

In 2013, CMS issued the “two midnight rule,” which revised its longstanding guidance to hospitals and physicians relating to when hospital inpatient admissions are deemed to be reasonable and necessary for payment under Medicare Part A. Under the two midnight rule, in addition to services that are designated as inpatient-only, surgical procedures, diagnostic tests and other treatments provided to Medicare beneficiaries are only payable as inpatient services under Medicare Part A when there is a reasonable expectation that the hospital care is medically necessary and will be required across two midnights, absent unusual circumstances. Stays expected to need fewer than two midnights of hospital care may be payable under Medicare Part A on a case-by-case basis. Quality Improvement Organizations (“QIO”) conduct post-payment reviews of short inpatient stays and refer claim denials to Medicare Administrative Contractors for payment adjustments. Beginning in 2016, QIOs may refer hospitals to Recovery Audit Contractors based on patterns such as high rates of claims denial after medical review or failure to improve after QIO educational intervention.

The increased scrutiny regarding short-stay admissions by Medicare and other payors has contributed, in part, to the decline in 1-day stays and the increase in observation patients experienced during the last two years. However, we cannot predict the impact on reimbursement of any changes or clarifications by CMS to the two midnight rule or its enforcement, whether by CMS or Congress. Further, there have been several challenges to the two midnight rule, primarily with regard to implementation of the rule itself and payment adjustments associated with the rule.

 

41


Table of Contents

The percentages of our insured and uninsured net hospital receivables are summarized as follows:

 

     March 31,
2016
    September 30,
2015
 

Insured receivables

     79.4     77.0

Uninsured receivables

     20.6     23.0
  

 

 

   

 

 

 

Total

     100.0     100.0
  

 

 

   

 

 

 

The percentages of hospital net receivables in summarized aging categories are as follows:

 

     March 31,
2016
    September 30,
2015
 

0 to 90 days

     64.2     63.0

91 to 180 days

     18.3     19.1

Over 180 days

     17.5     17.9
  

 

 

   

 

 

 

Total

     100.0     100.0
  

 

 

   

 

 

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

A summary of significant accounting policies is disclosed in Note 2 to the consolidated financial statements included in our 2015 Form 10-K. Our critical accounting policies are further described under the caption “Critical Accounting Policies and Estimates” in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2015 Form 10-K. There have been no changes in the nature of our critical accounting policies or the application of those policies since September 30, 2015.

 

42


Table of Contents

SELECTED OPERATING DATA

The following table sets forth certain unaudited operating data from continuing operations for each of the periods presented.

 

     Quarter Ended
March 31,
    Six Months Ended
March 31,
 
     2016     2015     2016     2015  

Acute care operations (1)

        

Number of hospital facilities at end of period

     17        15        17        15   

Licensed beds at end of period

     3,661        3,604        3,661        3,604   

Average length of stay (days) (2)

     5.0        5.1        4.9        5.1   

Occupancy rates (average beds in service)

     49.2     51.3     47.8     50.4

Admissions (3)

     25,948        25,814        51,408        51,682   

Adjusted admissions (4)

     48,606        47,601        97,304        95,508   

Patient days (5)

     130,108        131,347        253,996        261,190   

Adjusted patient days (4)

     243,722        242,204        480,760        482,679   

Surgeries

     16,413        15,771        34,524        32,582   

Emergency room visits

     111,012        109,605        216,359        215,945   

Net patient revenue per adjusted admission (6)

   $ 10,186      $ 9,827      $ 10,076      $ 9,729   

Outpatient revenue as a % of gross patient revenue

     46.6     45.8     47.2     45.9

Managed care operations

        

Health plan lives (7)

     512,600        247,400        512,600        247,400   

MSO lives (8)

     96,600        93,700        96,600        93,700   

Accountable care network lives (9)

     47,000        33,200        47,000        33,200   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total lives

     656,200        374,300        656,200        374,300   

Medical loss ratio (10)

     87.2     83.9     88.4     87.4

 

(1) Excludes the impact of our Nevada operations, which are reflected in discontinued operations. Includes St. Luke’s Behavioral Hospital in Phoenix, Arizona.
(2) Represents the average number of days that a patient stayed in our hospitals.
(3) Represents the total number of patients admitted to our hospitals that qualify for inpatient status. Management and investors use this number as a general measure of inpatient volume.
(4) Adjusted admissions and adjusted patient days are general measures of combined inpatient and outpatient volume. We compute adjusted admissions (or adjusted patient days) by multiplying admissions/patient days by gross patient revenue and then dividing that number by gross inpatient revenue.
(5) Represents the number of days our beds were occupied by inpatients over the period.
(6) Includes the impact of the provision for bad debts as a component of revenue.
(7) Represents total lives enrolled across all health plan product lines.
(8) Represents lives served by Health Choice’s MSO that provides management and administrative services to a large national insurer’s Medicaid plan members in the Tampa and “panhandle” regions of Florida.
(9) Represents attributed health plan member lives from other third-party payors for which Health Choice Preferred accountable care networks manage medical care and participating providers and Health Choice share associated financial risks. This excludes 51,300 and 34,900 attributed Health Choice plan member lives as of March 31, 2016 and 2015, respectively.
(10) Represents medical claims expense as a percentage of premium revenue, including claims paid to our hospitals.

 

43


Table of Contents

RESULTS OF OPERATIONS SUMMARY

Consolidated

The following table sets forth, for the periods presented, the results of our consolidated operations expressed in dollar terms and as a percentage of total revenue. Such information has been derived from our unaudited condensed consolidated statements of operations.

 

    Quarter Ended
March 31, 2016
    Quarter Ended
March 31, 2015
    Six Months Ended
March 31, 2016
    Six Months Ended
March 31, 2015
 

($ in thousands):

  Amount     Percentage     Amount     Percentage     Amount     Percentage     Amount     Percentage  

Revenues

               

Acute care revenue before provision for bad debts

  $ 598,194        $ 551,590        $ 1,179,595        $ 1,105,506     

Less: Provision for bad debts

    (98,881       (80,726       (190,696       (170,078  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

    499,313        60.8     470,864        67.6     988,899        60.9     935,428        68.5

Premium, service and other revenue

    321,974        39.2     225,963        32.4     635,236        39.1     430,937        31.5
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

    821,287        100.0     696,827        100.0     1,624,135        100.0     1,366,365        100.0

Costs and expenses

               

Salaries and benefits

    252,269        30.7     237,268        34.0     497,127        30.6     468,199        34.3

Supplies

    84,113        10.2     80,140        11.5     168,964        10.4     160,191        11.7

Medical claims

    268,030        32.6     176,059        25.3     534,737        32.9     352,031        25.8

Rentals and leases

    21,968        2.7     19,088        2.7     43,300        2.7     37,797        2.8

Other operating expenses

    148,137        18.1     113,746        16.3     277,887        17.1     226,967        16.6

Medicare and Medicaid EHR incentives

    (48     0.0     (2,235     (0.3 %)      (490     0.0     (5,650     (0.4 %) 

Interest expense, net

    34,033        4.1     31,854        4.6     66,643        4.1     64,217        4.7

Depreciation and amortization

    27,057        3.3     21,555        3.1     53,250        3.2     44,186        3.2

Management fees

    1,250        0.2     1,250        0.2     2,500        0.2     2,500        0.2
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

    836,809        101.9     678,725        97.4     1,643,918        101.2     1,350,438        98.8

Earnings (loss) from continuing operations before gain (loss) on disposal of assets and income taxes

    (15,522     (1.9 %)      18,102        2.6     (19,783     (1.2 %)      15,927        1.2

Gain (loss) on disposal of assets, net

    237        0.0     394        0.1     725        0.0     (454     (0.0 %) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

    (15,285     (1.9 %)      18,496        2.7     (19,058     (1.2 %)      15,473        1.1

Income tax expense (benefit)

    (4,885     (0.6 %)      9,747        1.4     (5,377     (0.3 %)      7,093        0.5
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) from continuing operations

    (10,400     (1.3 %)      8,749        1.3     (13,681     (0.9 %)      8,380        0.6

Earnings (loss) from discontinued operations, net of income taxes

    167        0.0     (1,806     (0.3 %)      (3,886     (0.2 %)      (3,306     (0.2 %) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss)

    (10,233     (1.3 %)      6,943        1.0     (17,567     (1.1 %)      5,074        0.4

Net earnings attributable to non-controlling interests

    (2,602     (0.3 %)      (2,763     (0.4 %)      (5,403     (0.3 %)      (5,050     (0.4 %) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net earnings (loss) attributable to IASIS Healthcare LLC

  $ (12,835     (1.6 %)    $ 4,180        0.6   $ (22,970     (1.4 %)    $ 24        0.0
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

44


Table of Contents

Acute Care Operations

The following table and discussion sets forth, for the periods presented, the results of our acute care operations expressed in dollar terms and as a percentage of total acute care revenue. Such information has been derived from our unaudited condensed consolidated statements of operations.

 

    Quarter Ended
March 31, 2016
    Quarter Ended
March 31, 2015
    Six Months Ended
March 31, 2016
    Six Months Ended
March 31, 2015
 

($ in thousands):

  Amount     Percentage     Amount     Percentage     Amount     Percentage     Amount     Percentage  

Acute care revenue

               

Acute care revenue before provision for bad debts

  $ 598,194        $ 551,590        $ 1,179,595        $ 1,105,506     

Less: Provision for bad debts

    (98,881       (80,726       (190,696       (170,078  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Acute care revenue

    499,313        99.1     470,864        99.2     988,899        99.2     935,428        99.2

Revenue between segments (1)

    4,499        0.9     3,894        0.8     8,458        0.8     7,836        0.8
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total acute care revenue

    503,812        100.0     474,758        100.0     997,357        100.0     943,264        100.0

Costs and expenses

               

Salaries and benefits

    233,755        46.4     222,892        46.9     461,710        46.3     441,166        46.8

Supplies

    83,864        16.6     79,993        16.8     168,337        16.9     159,889        17.0

Rentals and leases

    20,995        4.2     18,391        3.9     41,369        4.1     36,357        3.9

Other operating expenses

    130,623        25.9     96,680        20.4     242,802        24.3     196,938        20.9

Medicare and Medicaid EHR incentives

    (48     (0.0 %)      (2,235     (0.5 %)      (490     (0.0 %)      (5,650     (0.6 %) 

Interest expense, net

    34,033        6.8     31,854        6.7     66,643        6.7     64,217        6.8

Depreciation and amortization

    25,706        5.1     20,481        4.3     50,735        5.0     42,084        4.5

Management fees

    1,250        0.2     1,250        0.3     2,500        0.3     2,500        0.3
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

    530,178        105.2     469,306        98.9     1,033,606        103.6     937,501        99.4

Earnings (loss) from continuing operations before gain (loss) on disposal of assets and income taxes

    (26,366     (5.2 %)      5,452        1.1     (36,249     (3.6 %)      5,763        0.6

Gain (loss) on disposal of assets, net

    237        0.0     394        0.1     725        0.1     (454     (0.0 %) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings (loss) from continuing operations before income taxes

  $ (26,129     (5.2 %)    $ 5,846        1.2   $ (35,524     (3.5 %)    $ 5,309        0.6
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(1) Revenue between segments is eliminated in our consolidated results.

 

45


Table of Contents

Quarters Ended March 31, 2016 and 2015

Total acute care revenue — Total acute care revenue for the quarter ended March 31, 2016, was $503.8 million, an increase of $28.8 million or 6.1% compared to $474.8 million in the same prior year quarter. The increase in total acute care revenue during the quarter ended March 31, 2016, is comprised primarily of an increase in adjusted admissions of 2.1% and an increase in net patient revenue per adjusted admission of 3.6%, both compared to the same prior year quarter.

The provision for bad debts for the quarter ended March 31, 2016, was $98.9 million, an increase of $18.2 million or 22.5% compared to $80.7 million in the same prior year quarter. The increase in the provision for bad debts is due primarily to the growth of Exchange and managed care plans with higher deductibles and co-pays and the decrease in collections of such higher patient related balances.

Net adjustments to estimated third-party payor settlements, also known as prior year contractuals, resulted in an increase in total acute care revenue for the quarters ended March 31, 2016 and 2015, of $1.1 million and $0.3 million, respectively.

Salaries and benefits — Salaries and benefits expense for the quarter ended March 31, 2016, was $233.8 million, or 46.4% of total acute care revenue, compared to $222.9 million, or 46.9% of total acute care revenue in the same prior year quarter. Excluding the impact of stock-based compensation, salaries and benefits expense as a percentage of total acute care revenue was 46.1% for the quarter ended March 31, 2016, compared to 46.6% in the same prior year quarter. The improvement in our salaries and benefits expense as a percentage of total acute care revenue, excluding the impact of stock-based compensation, is the result of the implementation of labor productivity initiatives and a reduction in contract labor utilization.

Supplies — Supplies expense for the quarter ended March 31, 2016, was $83.9 million, or 16.6% of total acute care revenue, compared to $80.0 million, or 16.8% of total acute care revenue in the same prior year quarter.

Other operating expenses — Other operating expenses for the quarter ended March 31, 2016, were $130.6 million, or 25.9% of total acute care revenue, compared to $96.7 million, or 20.4% of total acute care revenue in the same prior year quarter. Other operating expenses were adversely impacted during the quarter ended March 31, 2016, by the unfavorable development of a small number of prior year professional liability claims totaling $11.9 million, while the prior year quarter included favorable development totaling $4.1 million associated with our professional liability reserves related to prior years. Excluding the impact of professional liability claims development, other operating expenses as a percentage of total acute care revenue for the quarter ended March 31, 2016 was 23.6%, compared to 21.2% in the same prior year quarter. Additionally, other operating expenses during the quarter ended March 31, 2016, have been impacted by $1.4 million of costs related to our ongoing clinical and revenue cycle system conversion.

Six Months Ended March 31, 2016 and 2015

Total acute care revenue — Total acute care revenue for the six months ended March 31, 2016, was $997.4 million, an increase of $54.1 million or 5.7% compared to $943.3 million in the same prior year period. The increase in total acute care revenue is comprised primarily of an increase in adjusted admissions of 1.9% and an increase in net patient revenue per adjusted admission of 3.6%, both compared to the same prior year period.

The provision for bad debts for the six months ended March 31, 2016, was $190.7 million, an increase of $20.6 million or 12.1% compared to $170.1 million in the same prior year period. The increase in the provision for bad debts is due primarily to the growth of Exchange and managed care plans with higher deductibles and co-pays and the decrease in collections of such higher patient related balances.

Net adjustments to estimated third-party payor settlements, also known as prior year contractuals, resulted in an increase in total acute care revenue for the six months ended March 31, 2016 and 2015, of $2.3 million and $2.1 million, respectively.

Salaries and benefits — Salaries and benefits expense for the six months ended March 31, 2016, was $461.7 million, or 46.3% of total acute care revenue, compared to $441.2 million, or 46.8% of total acute care revenue in the same prior year period. Excluding the impact of stock-based compensation, salaries and benefits expense as a percentage of total acute care revenue was 46.0% for the six months ended March 31, 2016, compared to 46.4% in the same prior year period. The improvement in our salaries and benefits expense as a percentage of total acute care revenue, excluding the impact of stock-based compensation, is the result of the implementation of labor productivity initiatives and a reduction in contract labor utilization.

Supplies — Supplies expense for the six months ended March 31, 2016, was $168.3 million, or 16.9% of total acute care revenue, compared to $159.9 million, or 17.0% of total acute care revenue in the same prior year period.

 

46


Table of Contents

Other operating expenses — Other operating expenses for the six months ended March 31, 2016, were $242.8 million, or 24.3% of total acute care revenue, compared to $196.9 million, or 20.9% of total acute care revenue in the same prior year period. Other operating expenses were adversely impacted during the six months ended March 31, 2016, by the unfavorable development of a small number of prior year professional liability claims totaling $11.9 million, while the prior year period included favorable development totaling $4.1 million associated with our professional liability reserves related to prior years. Excluding the impact of professional liability claims development, other operating expenses as a percentage of total acute care revenue for the six months ended March 31, 2016, was 23.2%, compared to 21.3% in the same prior year period. Additionally, other operating expenses during the six months ended March 31, 2016, have been impacted by $2.3 million of costs related to our ongoing clinical and revenue cycle system conversion.

 

47


Table of Contents

Managed Care Operations

The following table and discussion sets forth, for the periods presented, the results of our managed care operations expressed in dollar terms and as a percentage of premium, service and other revenue. Such information has been derived from our unaudited condensed consolidated statements of operations.

 

    Quarter Ended
March 31, 2016
    Quarter Ended
March 31, 2015
    Six Months Ended
March 31, 2016
    Six Months Ended
March 31, 2015
 

($ in thousands):

  Amount     Percentage     Amount     Percentage     Amount     Percentage     Amount     Percentage  

Premium, service and other revenue

               

Premium revenue

  $ 312,394        96.9   $ 214,438        94.9   $ 614,459        96.7   $ 411,624        95.5

Service and other revenue

    9,580        3.1     11,525        5.1     20,777        3.3     19,313        4.5
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Premium, service and other revenue

    321,974        100.0     225,963        100.0     635,236        100.0     430,937        100.0

Costs and expenses

               

Salaries and benefits

    18,514        5.8     14,376        6.4     35,417        5.6     27,033        6.3

Supplies

    249        0.1     147        0.1     627        0.1     302        0.1

Medical claims (1)

    272,529        84.6     179,953        79.6     543,195        85.5     359,867        83.5

Rentals and leases

    973        0.3     697        0.3     1,931        0.3     1,440        0.3

Other operating expenses

    17,514        5.4     17,066        7.6     35,085        5.5     30,029        7.0

Depreciation and amortization

    1,351        0.4     1,074        0.5     2,515        0.4     2,102        0.5
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and expenses

    311,130        96.6     213,313        94.4     618,770        97.4     420,773        97.6
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Earnings before income taxes

  $ 10,844        3.4   $ 12,650        5.6   $ 16,466        2.6   $ 10,164        2.4
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(1) Medical claims paid to our hospitals of $4.5 million and $3.9 million for the quarters ended March 31, 2016 and 2015, respectively, and $8.5 million and $7.8 million for the six months ended March 31, 2016 and 2015, respectively, are eliminated in our consolidated results.

Quarters Ended March 31, 2016 and 2015

Premium revenue — Premium revenue was $312.4 million for the quarter ended March 31, 2016, an increase of $98.0 million or 45.7%, compared to $214.4 million in the same prior year quarter. The increase in premium revenue was driven by the addition of HCIC, our Northern Arizona joint venture, which became effective on October 1, 2015, as well as membership growth in our other health plan product lines. As of March 31, 2016, total lives served across all health plans increased 75.3%, compared to the same prior year quarter. Excluding HCIC, total health plan lives increased 14.9% as of March 31, 2016, when compared to the same prior year period.

Service and other revenue — Service and other revenue was $9.6 million for the quarter ended March 31, 2016, compared to $11.5 million in the same prior year quarter.

Salaries and benefits — Salaries and benefits expense for the quarter ended March 31, 2016, was $18.5 million, or 5.7% of premium, service and other revenue, compared to $14.4 million, or 6.4% of premium, service and other revenue in the same prior year quarter. Excluding the impact of HCIC, salaries and benefits expense for the quarter was 6.1% of premium, service and other revenue, compared to 6.4% in the same prior year quarter.

Medical claims — Medical claims expense was $272.5 million for the quarter ended March 31, 2016, compared to $180.0 million in the same prior year quarter. Medical claims expense as a percentage of premium revenue, or medical loss ratio (“MLR”), related to our health plan products was 87.2% for the quarter ended March 31, 2016, compared to 83.9% in the same prior year quarter. Excluding the impact of HCIC and premium revenue associated with Arizona’s quality program, our MLR was 86.9% for the quarter ended March 31, 2016, compared to 85.6% in the same prior year quarter, driven primarily by an increase in specialty pharmacy and other drug related utilization and costs.

Other operating expenses — Other operating expenses for the quarter ended March 31, 2016, were $17.5 million, or 5.5% of premium, service and other revenue, compared to $17.1 million, or 7.6% of premium, service and other revenue in the same prior year quarter. Excluding the impact of HCIC, other operating expenses were 5.0% of premium, service and other revenue,

 

48


Table of Contents

compared to 7.6% in the same prior year quarter. The decrease in other operating expenses as a percentage of premium, service and other revenue is due primarily to leveraging the growth in membership and premium revenue, along with the implementation of initiatives to reduce costs, including professional and consulting fees.

Six Months Ended March 31, 2016 and 2015

Premium revenue — Premium revenue was $614.5 million for the six months ended March 31, 2016, an increase of $202.8 million or 49.3%, compared to $411.6 million in the same prior year period. The increase in premium revenue was driven by the addition of HCIC, our Northern Arizona joint venture, which became effective on October 1, 2015, as well as membership growth in our other health plan product lines. As of March 31, 2016, total lives served across all health plans increased 75.3%, compared to the same prior year period. Excluding HCIC, total health plan lives increased 14.9% as of March 31, 2016, when compared to the same prior year period.

Service and other revenue — Service and other revenue was $20.8 million for the six months ended March 31, 2016, compared to $19.3 million in the same prior year period.

Salaries and benefits — Salaries and benefits expense for the six months ended March 31, 2016, was $35.4 million, or 5.6% of premium, service and other revenue, compared to $27.0 million, or 6.3% of premium, service and other revenue in the same prior year period. Excluding the impact of HCIC, salaries and benefits expense for the six months ended March 31, 2016, was 6.0% of premium, service and other revenue, compared to 6.3% in the same prior year period.

Medical claims — Medical claims expense was $543.2 million for the six months ended March 31, 2016, compared to $359.9 million in the same prior year period. Medical claims expense as a percentage of premium revenue, or MLR, related to our health plan products was 88.4% for the six months ended March 31, 2016, compared to 87.4% in the same prior year period. Excluding the impact of HCIC and premium revenue associated with Arizona’s quality program, our MLR was 88.4% for the six months ended March 31, 2016, compared to 88.3% in the same prior year period.

Other operating expenses — Other operating expenses for the six months ended March 31, 2016, were $35.1 million, or 5.5% of premium, service and other revenue, compared to $30.0 million, or 7.0% of premium, service and other revenue in the same prior year period. Excluding the impact of HCIC, other operating expenses were 5.1% of premium, service and other revenue, compared to 7.0% in the same prior year period. The decrease in other operating expenses as a percentage of premium, service and other revenue is due primarily to leveraging the growth in membership and premium revenue, along with the implementation of initiatives to reduce costs, including professional and consulting fees.

 

49


Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

Overview of Cash Flow Activities for the Six Months Ended March 31, 2016 and 2015

Our cash flows are summarized as follows (in thousands):

 

     Six Months Ended
March 31,
 
     2016      2015  

Cash flows from operating activities

   $ 78,689       $ 17,188   

Cash flows from investing activities

   $ (69,665    $ (19,618

Cash flows from financing activities

   $ (19,990    $ (12,170

Operating Activities

Cash flows provided by operating activities were $78.7 million for the six months ended March 31, 2016, compared to cash flows provided by operating activities of $17.2 million in the same prior year period. Included in operating activities for the six months ended March 31, 2016, was $3.3 million related to our current conversion to a new integrated clinical and revenue cycle system. The increase in cash flows from operating activities is due primarily to the growth in premium revenue at our managed care division, as well as the receipt of Texas supplemental funding on a faster time frame than we have experienced in previous periods.

At March 31, 2016, we had $436.3 million in net working capital, compared to $508.7 million at September 30, 2015. Net accounts receivable increased $24.7 million to $342.4 million at March 31, 2016, from $317.7 million at September 30, 2015.

Investing Activities

Cash flows used in investing activities were $69.7 million for the six months ended March 31, 2016, compared to $19.6 million in the same prior year period, which included $41.4 million in proceeds from the sale of our Nevada operations in January 2015. Included in investing activities for the six months ended March 31, 2016, was the impact of a final working capital settlement associated with the sale of our Nevada operations that resulted in a cash outflow totaling $5.9 million. Additionally, included in investing activities for the six months ended March 31, 2016, was $8.2 million related to our current conversion to a new integrated clinical and revenue cycle system.

Financing Activities

Cash flows used in financing activities were $20.0 million for the six months ended March 31, 2016, compared to $12.2 million in the same prior year period. Distributions to non-controlling interests were $5.6 million for the six months ended March 31, 2016, compared to $4.4 million in the same prior year period. During six months ended March 31, 2016, we made finance obligation payments totaling $1.8 million related to our current conversion to a new integrated clinical and revenue cycle system and $5.2 million in payments associated with the extension of our revolving credit facility in February 2016.

Capital Resources

As of March 31, 2016, we had the following debt arrangements:

 

    up to $1.232 billion senior secured credit facilities; and

 

    $849.9 million in 8.375% senior notes due 2019.

At March 31, 2016, amounts outstanding under our senior secured credit facilities consisted of $974.3 million in term loans. In addition, we had $83.7 million in letters of credit outstanding under the revolving credit facility. The weighted average interest rate of outstanding borrowings under the senior secured credit facilities was 4.5% for both the quarter and six months ended March 31, 2016, compared to 4.6% in the same prior year periods.

Amended Term Loan Facility

We are a party to a senior credit agreement (the “Amended and Restated Credit Agreement”) with Wilmington Trust, National Association, as administrative agent, which provides for a $1.025 billion senior secured term loan facility maturing in May 2018 (the “Term Loan Facility”). Principal under the Term Loan Facility is due in equal quarterly installments in an aggregate annual amount equal to 1% of the principal amount of $1.007 billion outstanding as of the effective date, February 20, 2013, of a repricing amendment, with the remaining balance due upon maturity of the Term Loan Facility.

Borrowings under the Term Loan Facility bear interest at a rate per annum equal to, at our option, either (1) a base rate determined by reference to the highest of (a) the federal funds rate plus 0.50%, (b) the prime rate (determined by reference to The Wall Street Journal) and (c) a one-month LIBOR rate, subject to a floor of 1.25%, plus 1.00%, in each case, plus a margin of 2.25% per annum or (2) the LIBOR rate for the interest period relevant to such borrowing, subject to a floor of 1.25%, plus a margin of 3.25% per annum.

 

50


Table of Contents

The Term Loan Facility is unconditionally guaranteed by IAS and certain of our subsidiaries (collectively, the “Subsidiary Guarantors”; IAS and the Subsidiary Guarantors, the “Guarantors”) and is required to be guaranteed by all of our future material wholly-owned subsidiaries, subject to certain exceptions. All obligations under the Amended and Restated Credit Agreement are secured, subject to certain exceptions, by substantially all of our assets and the assets of the Guarantors, including (1) a pledge of 100% of our equity interests and the equity interests held by us and the Subsidiary Guarantors, subject to certain exceptions, (2) mortgage liens on all of our material real property and that of the Guarantors and (3) all proceeds of the foregoing.

The Amended and Restated Credit Agreement requires us to mandatorily prepay borrowings under the Term Loan Facility with net cash proceeds of certain asset dispositions, following certain casualty events, following certain borrowings or debt issuances and from a percentage of annual excess cash flow.

The Amended and Restated Credit Agreement contains certain restrictive covenants, including, among other things: (1) limitations on the incurrence of debt and liens; (2) limitations on investments other than, among other exceptions, certain acquisitions that meet certain conditions; (3) limitations on the sale of assets outside of the ordinary course of business; (4) limitations on dividends and distributions; and (5) limitations on transactions with affiliates, in each case, subject to certain exceptions. The Amended and Restated Credit Agreement also contains certain customary events of default, including, without limitation, a failure to make payments under the Term Loan Facility, cross-defaults, certain bankruptcy events and certain change of control events.

Revolving Credit Facility

We are a party to a revolving credit agreement (the “Revolving Credit Agreement”) with JPMorgan Chase Bank, N.A. (“JPMorgan”), as administrative agent, which provides for a $207.4 million senior secured revolving credit facility, of which up to $125.0 million may be utilized for the issuance of letters of credit (the “Revolving Credit Facility”). The Revolving Credit Facility matures in February 2021 (the “Stated Revolver Maturity Date”), provided that, if prior to the Stated Revolver Maturity Date, (x) any loans are outstanding under the Term Loan Facility on the date that is 91 days prior to the maturity date under the Term Loan Facility (such date, the “Springing Term Maturity Date”) or (y) any notes are outstanding under our indenture, dated as of May 3, 2011, by and among IASIS, IAS and The Bank of New York Mellon Trust Company, N.A., as Trustee, relating to our 8.375% Senior Notes due 2019 (the “Indenture”), on the date that is 91 days prior to the maturity date under the Indenture (such date, the “Springing Notes Maturity Date”), then the maturity date will automatically become the earlier of the Springing Term Maturity Date or the Springing Notes Maturity Date.

The Revolving Credit Agreement provides us with the right to request additional commitments under the Revolving Credit Facility without the consent of the lenders thereunder, subject to a cap on aggregate commitments of $300.0 million, a pro forma senior secured net leverage ratio (as defined in the Revolving Credit Agreement) of less than or equal to 3.75 to 1.00 and customary conditions precedent.

The Revolving Credit Facility does not require installment payments prior to maturity.

Borrowings under the Revolving Credit Facility bear interest at a rate per annum equal to, at our option, either (1) a base rate determined by reference to the highest of (a) the prime rate of JPMorgan, (2) the federal funds rate plus 0.50% and (3) a LIBOR rate subject to certain adjustments plus 1.00%, in each case, plus a margin of 2.50% per annum or (2) the LIBOR rate for the interest period relevant to such borrowing, plus a margin of 3.50% per annum. In addition to paying interest on outstanding principal under the Revolving Credit Facility, we are required to pay a commitment fee on the unutilized commitments under the Revolving Credit Facility, as well as pay customary letter of credit fees and agency fees.

The Revolving Credit Facility is unconditionally guaranteed by the Guarantors and is required to be guaranteed by all of our future material wholly-owned subsidiaries, subject to certain exceptions. All obligations under the Revolving Credit Agreement are secured, subject to certain exceptions, by substantially all of our assets and the assets of the Guarantors, including (1) a pledge of 100% of our equity interests and the equity interests held by us and the Subsidiary Guarantors, subject to certain exceptions, (2) mortgage liens on all of our material real property and that of the Guarantors and (3) all proceeds of the foregoing.

The Revolving Credit Agreement contains restrictive covenants and events of default substantially similar to the restrictive covenants and events of default in the Amended and Restated Credit Agreement; provided, that under the Revolving Credit Agreement, we are required to maintain, on a quarterly basis, a maximum senior secured gross leverage ratio (as defined in the Revolving Credit Agreement). In addition, certain of the baskets available to us under the negative covenants in the Amended and Restated Credit Agreement are suspended under the Revolving Credit Agreement until such time, if any, as we have consummated a qualifying underwritten public offering and achieved a specified total gross leverage ratio (as defined in the Revolving Credit Agreement).

 

51


Table of Contents

8.375% Senior Notes due 2019

We, together with our wholly owned subsidiary IASIS Capital Corporation (together, the “Issuers”) issued an $850.0 million aggregate principal amount of Senior Notes, which mature on May 15, 2019, pursuant to the Indenture. The Indenture provides that the Senior Notes are general unsecured, senior obligations of the Issuers, and initially will be unconditionally guaranteed on a senior unsecured basis by certain of our subsidiaries.

At March 31, 2016, the outstanding principal balance of the Senior Notes was $849.9 million. The Senior Notes bear interest at a rate of 8.375% per annum, payable semi-annually, in cash in arrears, on May 15 and November 15 of each year.

The Issuers may redeem the Senior Notes in whole or in part, at any time at a price equal to 102.094% of the aggregate principal amount of the Senior Notes plus accrued and unpaid interest and special interest, if any, to but excluding the redemption date, subject to compliance with certain conditions. Each subsequent year the redemption price declines 2.094 percentage points until 2017, at which point and thereafter the redemption price is equal to 100% of the aggregate principal amount of the Senior Notes plus accrued and unpaid interest and special interest, if any, to but excluding the redemption date.

The Indenture contains covenants that limit our (and our restricted subsidiaries’) ability to, among other things: (1) incur additional indebtedness or liens or issue disqualified stock or preferred stock; (2) pay dividends or make other distributions on, redeem or repurchase our capital stock; (3) sell certain assets; (4) make certain loans and investments; (5) enter into certain transactions with affiliates; (6) impose restrictions on the ability of a subsidiary to pay dividends or make payments or distributions to us and our restricted subsidiaries; and (7) consolidate, merge or sell all or substantially all of our assets. These covenants are subject to a number of important limitations and exceptions.

The Indenture also provides for events of default, which, if any of them occurs, may permit or, in certain circumstances, require the principal, premium, if any, interest and any other monetary obligations on all the then outstanding Senior Notes to be due and payable immediately. If we experience certain kinds of changes of control, we must offer to purchase the Senior Notes at 101% of their principal amount, plus accrued and unpaid interest and special interest, if any, to but excluding the repurchase date. Under certain circumstances, we will have the ability to make certain payments to facilitate a change of control transaction and to provide for the assumption of the Senior Notes by a new parent company resulting from such change of control transaction. If such change of control transaction is facilitated, the Issuers will be released from all obligations under the Indenture and the Issuers and the trustee will execute a supplemental indenture effectuating such assumption and release.

Credit Ratings

The table below summarizes our corporate rating, as well as our credit ratings for the Senior Secured Credit Facilities and Senior Notes as of the date of this Report:

 

     Moody’s    Standard & Poor’s

Corporate credit

   B2    B

Senior secured term loan facility

   Ba3    B

Senior Notes

   Caa1    CCC+

Outlook

   Stable    Stable

Other

We executed interest rate swaps with Citibank, N.A. (“Citibank”) and Barclays Bank PLC (“Barclays”), as counterparties, with notional amounts totaling $350.0 million, of which $50.0 million expired on September 30, 2014 and $100.0 million expired on September 30, 2015. The remaining agreement was effective March 28, 2013 and expires September 30, 2016. Under the remaining agreement, we are required to make quarterly fixed rate payments to our counterparty at an annual rate of 2.2%. The counterparty is obligated to make quarterly floating rate payments to us based on the three-month LIBOR rate, subject to a floor of 1.25%.

Capital Expenditures

We plan to finance our proposed capital expenditures with cash generated from operations, borrowings under our Senior Secured Credit Facilities and other capital sources that may become available. We continue to expect our capital expenditures for fiscal 2016 to be between $145.0 million to $155.0 million, including $37.0 million to $42.0 million in hardware and software costs related to the conversion to our new clinical and revenue information system.

 

52


Table of Contents

Liquidity

We rely on cash generated from our operations as our primary source of liquidity, as well as available credit facilities, project and bank financings and the issuance of long-term debt. From time to time, we have also utilized operating lease transactions that are sometimes referred to as off-balance sheet arrangements. We expect that our future funding for working capital needs, capital expenditures, long-term debt repayments and other financing activities will continue to be provided from some or all of these sources. Each of our existing and projected sources of cash is impacted by operational and financial risks that influence the overall amount of cash generated and the capital available to us. For example, cash generated by our business operations may be impacted by, among other things, economic downturns, federal and state budget initiatives, weather-related catastrophes and adverse industry conditions. Our future liquidity will be impacted by our ability to access capital markets, which may be restricted due to our credit ratings, general market conditions, leverage capacity and by existing or future debt agreements. For a further discussion of risks that can impact our liquidity, see Item 1A, “Risk Factors” in our 2015 Form 10-K.

Including available cash at March 31, 2016, we have available liquidity as follows (in millions):

 

Cash and cash equivalents

   $ 367.5   

Cash collateral for certain letters of credit and other items

     (4.7

Available capacity under our senior secured revolving credit facility

     123.7   
  

 

 

 

Net available liquidity at March 31, 2016

   $ 486.5   
  

 

 

 

Net available liquidity assumes 100% participation from all lenders currently committed under our Revolving Credit Facility. In addition to our available liquidity, we expect to generate sufficient operating cash flows in fiscal 2016. We also intend to utilize proceeds from our financing activities as needed.

Based upon our current and anticipated level of operations, we believe we have sufficient liquidity to meet our cash requirements over the short-term (next 12 months) and over the next two years. In evaluating the sufficiency of our liquidity for the short-term, we considered the expected cash flow to be generated by our operations, cash on hand and the available borrowings under our Senior Secured Credit Facilities, compared to our anticipated cash requirements for debt service, working capital, capital expenditures and the payment of taxes, as well as funding requirements for long-term liabilities.

We are unable at this time to extend our evaluation of the sufficiency of our liquidity beyond two years. In addition, we cannot assure you that our operating performance will generate sufficient cash flow from operations or that future borrowings will be available under our Senior Secured Credit Facilities, or otherwise, to enable us to grow our business, service our indebtedness, or make anticipated capital expenditures and tax payments. For more information, see Item 1A. “Risk Factors” in our 2015 Form 10-K.

We and our subsidiaries, affiliates, IAS and/or significant stockholders of IAS may from time to time seek to retire or purchase our outstanding debt (including publicly issued debt) through cash purchases and/or exchanges, in open market purchases, privately negotiated transactions, by tender offer or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

One element of our business strategy is to selectively pursue acquisitions and strategic alliances in existing and new markets. Any acquisitions or strategic alliances may result in the incurrence, or assumption by us, of additional indebtedness. We continually assess our capital needs and may seek additional financing, including debt or equity as considered necessary to fund capital expenditures and potential acquisitions or for other corporate purposes. Our future operating performance and our ability to service or refinance our debt will be subject to future economic conditions and to financial, business and other factors, many of which are beyond our control. For more information, see Item 1A. “Risk Factors” in our 2015 Form 10-K.

Seasonality

The patient volumes and total revenue of our healthcare operations are subject to seasonal variations and generally are greater during the quarter ended March 31 than other quarters. These seasonal variations are caused by a number of factors, including seasonal cycles of illness, climate and weather conditions in our markets, vacation patterns of both patients and physicians and other factors relating to the timing of elective procedures.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are subject to market risk from exposure to changes in interest rates based on our financing, investing and cash management activities. We do not, however, hold or issue financial instruments or derivatives for trading or speculative purposes. At March 31, 2016, the following components of our Senior Secured Credit Facilities bear interest at variable rates at specified margins above either the agent bank’s alternate base rate or the LIBOR rate: (i) a $1.025 billion, seven-year term loan; and (ii) a $207.4 million revolving credit facility. As of March 31, 2016, we had outstanding variable rate debt of $974.3 million.

 

53


Table of Contents

We have managed our market exposure to changes in interest rates by implementing a comprehensive interest rate hedging strategy that includes converting variable rate debt to fixed rate debt. We have previously executed interest rate swaps for non-trading and non-speculative purposes with Citibank and Barclays, as counterparties, with notional amounts totaling $350.0 million, of which $50.0 million expired on September 30, 2014 and $100.0 million expired on September 30, 2015. The remaining agreement was effective March 28, 2013 and expires September 30, 2016, and has an annual rate of 2.2%. Our interest rate hedging agreement exposes us to credit risk in the event of non-performance by our counterparty, Citibank. However, we do not anticipate non-performance by our counterparty.

Although changes in the alternate base rate or the LIBOR rate would affect the cost of funds borrowed in the future, we believe the effect, if any, of reasonably possible near-term changes in interest rates on our remaining variable rate debt or our consolidated financial position, results of operations or cash flows would not be material. Holding other variables constant, including levels of indebtedness, a 0.125% increase in current interest rates would have no estimated impact on pre-tax earnings and cash flows for the next 12 month period given the 1.25% LIBOR floor that exists in our Term Loan Facility.

We currently believe we have adequate liquidity to fund operations during the near term through the generation of operating cash flows, cash on hand and access to our Revolving Credit Facility. Our ability to borrow funds under our Revolving Credit Facility is subject to, among other things, the financial viability of the participating financial institutions. While we do not anticipate any of our current lenders defaulting on their obligations, we are unable to provide assurance that any particular lender will not default at a future date.

 

Item 4. Controls and Procedures

Evaluations of Disclosure Controls and Procedures

Under the supervision and with the participation of our management team, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of March 31, 2016. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2016.

Changes in Internal Control Over Financial Reporting

During the second fiscal quarter of the period covered by this Report, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

None.

 

Item 1A. Risk Factors

Reference is made to the factors set forth under the caption “Forward-Looking Statements” in Part I, Item 2 of this Form 10-Q and other risk factors disclosed in our 2015 Form 10-K, which are incorporated herein by reference. There have not been any material changes to the risk factors previously disclosed in our 2015 Form 10-K.

 

Item 5. Other Information

The Company has authorized, and entered into as of the date of this Quarterly Report on Form 10-Q, amendments that affect extensions, until March 30, 2019, of the existing employment agreements of its Chief Executive Officer, Chief Financial Officer and Chief Operating Officer.

 

Item 6. Exhibits

 

(a) List of Exhibits:

Exhibits: See the Index to Exhibits at the end of this report, which is incorporated herein by reference.

 

54


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    IASIS HEALTHCARE LLC
Date: May 16, 2016     By:  

/s/ John M. Doyle

      John M. Doyle
      Chief Financial Officer

 

55


Table of Contents

EXHIBIT INDEX

 

Exhibit

No.

  

Description

  10.1    Amendment No. 3, dated as of February 17, 2016, among IASIS Healthcare LLC, IASIS Healthcare Corporation, the lenders party thereto, Bank of America, N.A., as administrative agent and Wilmington Trust, National Association, as successor administrative agent, and attached thereto as Exhibit A, the Amended and Restated Credit Agreement, dated as of May 3, 2011 as amended as of February 17, 2016, among IASIS Healthcare LLC, IASIS Healthcare Corporation, Wilmington Trust, National Association, as administrative agent and collateral agent, and each lender from time to time party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on February 22, 2016 (Comm. File No. 333-117362)).
  10.2    Revolving Credit Agreement, dated as of February 17, 2016, among IASIS Healthcare LLC, IASIS Healthcare Corporation, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, swing line lender and L/C Issuer (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on February 22, 2016 (Comm. File No. 333-117362)).
  31.1    Certification of Principal Executive Officer pursuant to Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  31.2    Certification of Principal Financial Officer pursuant to Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
101    The following financial information from our quarterly report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 16, 2016, formatted in Extensible Business Reporting Language (XBRL): (i) the condensed consolidated balance sheets at March 31, 2016 and September 30, 2015, (ii) the condensed consolidated statements of operations for the quarters and six months ended March 31, 2016 and 2015, (iii) the condensed consolidated statements of comprehensive income (loss) for the quarters and six months ended March 31, 2016 and 2015, (iv) the condensed consolidated statement of equity, (v) the condensed consolidated statements of cash flows for the six months ended March 31, 2016 and 2015, and (vi) the notes to the condensed consolidated financial statements (tagged as blocks of text). (1)

 

(1) The XBRL related information in Exhibit 101 to this quarterly report on Form 10-Q shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

 

56